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Abstract 
 
Introduction: Diabetic retinopathy (DR) is a major source of visual loss in the world, 
including North America. A number of hyperglycemia-related pathways have been 
associated with DR onset and progression. Disturbances in the retinal vasculature appear 
to play a vital role in DR, resulting in biochemical and functional vascular changes. 
Therefore, this study investigated retinal blood oxygen saturation and angiogenic and 
inflammatory biomarkers in DR.  
Methods: Chapter 3 and 5: FD-OCT Doppler blood flow was non-invasively measured 
using a prototype system based on the RTVue (Optovue Inc., USA). A minimum of six 
separate FD-OCT Doppler measurements was acquired. Chapter 4, 5, 7: Non-invasive 
hyperspectral retinal (HR) imaging was acquired in participants with mild-to-moderate 
NPDR and age-matched controls. For each subject, six repeated HRC images were 
acquired at wavelengths of 586 and 605nm.  
Results: Chapter 3: The individual COV medians for retinal blood flow were 7.5% and 
9.2% for young and elderly subjects, respectively. The group mean CORs for retinal 
blood flow for young participants were 6.4µl/min and for elderly subjects were 
10.5µl/min. Chapter 4: Retinal blood oxygen saturation in the arterioles of healthy 
controls was 92.97±1.6%, and in the venules was 55.90±4.8%. Retinal blood oxygen 
saturation for diabetic subjects with NPDR was significantly higher at 94.65±2.2% 
(p=0.015) in the arterioles and 64.13±4.3% (p<0.001) in the venules. Chapter 5: Total 
retinal blood flow was significantly lower in NPDR when compared to controls (42.66 vs 
32.97; p=0.004). There was no relationship between total retinal blood flow and venular 
oxygen saturation (r=0.2). Chapter 6: Angiopoietin 2, IL-8, HGF was significantly higher 
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in NPDR patients than in control patients (p=0.005, p=0.034, p=0.018, respectively) and 
EGF was significantly lower in NPDR patients when compared to controls (p=0.025). 
Chapter 7: The study demonstrated a correlation between retinal blood oxygen saturation 
and Ang 2, HGF and EGF but did not find any correlation for IL-8, TGF-β even though 
these biomarkers were significantly higher in the diabetic group.   
Conclusions: Chapter 3: Doppler OCT gave consistent and repeatable blood flow 
measurements within retinal venules in normal subjects. Chapter 4: A higher blood 
oxygen saturation could be the result of less oxygen consumtion due to cell death. 
Chapter 5: There is no correlation between retinal blood flow and retinal blood oxygen 
saturation. Chapter 6: Further investigation of Ang 2, HGF, IL-8, EGF, TGF-β could be 
used to better understand the pathophysiology of DR. Chapter 7: The result of this study 
revealed a relationship between the biomarkers that might result in cell death and higher 
retinal blood oxygen saturation. 
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1 Introduction 
1.1 Retinal Oxygen Supply  
The retina is a tissue with extraordinary metabolic demand, especially for key molecules 
such as oxygen 1,2. The retina is constantly active and converts light into neural signals and 
this activity increases in the dark as well (with increase in oxygen consumption). The 
retinal cells demand a continuous oxygen supply. Nonetheless, a vascular network situated 
in front of the photoreceptors would affect with transmission of light to the photoreceptors. 
The outer 1/3 to 1/2 of the retina collects most of its oxygen demand via the much greater 
choroidal microcirculation. The choroid nourishes the outer retinal layers, including the 
photoreceptors 3,4. The oxygen diffusion from choroid to the layer of photoreceptors results 
in an extraordinary concentration of oxygen 2. The uveal system, specifically the 
choriocapillaries, feeds the outer retinal layers closest to Bruch’s membrane. The short 
posterior ciliary arteries directly supply the choroid posteriorly, whereas the long posterior 
ciliary arteries travel in the suprachoroidal space anteriorly then supply the choroid 
anteriorly via recurrent branches. The retinal inner layers are nourished by the retinal blood 
vessels. The inner retina maintains its blood via the aortic artery, common carotid arteries, 
internal carotid artery, ophthalmic artery and finally the central retinal artery (CRA). The 
CRA enters the optic nerve 10-15 mm behind the globe and runs forward in the central 
section of the nerve along with the central retinal vein. The CRA supplies the inner two 
thirds of the retina, the furthermost anterior share of the superficial nerve fiber layer of the 
optic nerve head and to some extent the retrolaminar optic nerve 3,4.  
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1.2 Structure of the Retinal Vessels 
Retinal vessels are made of 3 layers: (1) adventitia, (2) smooth muscle cells, and (3) 
endothelial cells.  
The CRA and specifically the downstream arterioles are considered to be responsible for 
blood flow regulation to the capillaries; the arterioles govern downstream retinal blood 
flow and as a result are termed as “resistance” vessels. Retinal capillaries are composed of 
a basement membrane containing pericytes covered by a single layer of endothelium. 
Capillaries are responsible for facilitating exchange (often termed “exchange” vessels) of 
metabolites at the tissue level 5. The tight junctions between the endothelial cells create the 
inner blood retinal barrier (BRB), inhibiting leakage of blood components into the retinal 
tissue for ideal retinal functioning. 
1.3 Blood-Ocular Barrier  
The blood-ocular barrier system is designed in 2 forms: the blood-aqueous barrier and the 
BRB. The blood-aqueous barrier is made of an epithelial barrier found in the non-
pigmented layer of the ciliary epithelium and in the posterior iridial epithelium, and by the 
iridial vessel’s endothelium. The BRB is a physiologic barrier that controls flux of water, 
ion, and protein into and out of the retina. It contains inner and outer modules, the inner 
BRB is designed with tight junctions between retinal capillary endothelial cells and the 
outer BRB is made of tight junctions between retinal pigment epithelial cells.  
The BRB is critical for sustaining normal visual function. Variations of the BRB present a 
vital role in the development of retinal diseases such as diabetic retinopathy and age-related 
macular degeneration. Diabetic retinopathy is commenced by a variation of the inner BRB 
and Macular edema is a direct result of changes of the BRB 6.  
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1.4 Retinal Blood Flow 
A constant circulation of blood in the cardiovascular network is termed as blood flow. This 
is necessary for the transportation of nutrients, hormones, oxygen, carbon dioxide, 
metabolic waste in the body to sustain metabolism at cellular level, pH, body temperature, 
and the protect from microbial and mechanical disturbances.  The principles that manage 
the flow within a cylindrical tube can be applied to the movement of blood cells within a 
blood vessel. Particularly, the flow of fluid within a tube is determined by two factors: 1) 
the perfusion pressure difference between the two ends of the vessel 2) vascular resistance, 
since the impediment to blood flow in a vessel is resistance. But there is not any straight 
method to measure the resistance. Resistance to blood flow within a vascular system differs 
upon the size factors of individual vessels (i.e. length and diameter), the way they are 
prearranged in the vascular system (i.e. series and parallel arrangements), physical 
individualities of the blood (i.e. viscosity, laminar flow versus turbulent flow) and 
extravascular mechanical forces acting upon the vasculature (in terms of the eye, the 
intraocular pressure) 7. 
Ohm’s law explains the same physical issues that impact the flow of any fluid, and are 
based on a fundamental law of physics 8. 
𝑄 = ∆𝑃𝑅  
Flow (Q) is related to the difference in pressure (ΔP) between the two ends of the tube and 
inversely correlated to the resistance (R).  
The rate of the blood flow across a vessel for a particular pressure difference is termed the 
conductance. Conductance equals the reciprocal of resistance: 
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𝐶𝑜𝑛𝑑𝑢𝑐𝑡𝑎𝑛𝑐𝑒 = 1𝑅𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒 
Once the blood flow is unstable, minor changes in the diameter of a vessel creates 
substantial changes in the vessel’s ability to conduct blood. The conductance of the vessel 
increases in proportion to the fourth power of the diameter, in agreement with the following 
formula: 7 
Conductance ∝ Diameter4 
𝑹 ∝ 𝜼𝑳𝒓𝟒  
Where R is vessel resistance, L is length, η is blood viscosity, and r4 is the fourth power of 
radius. 
1.5 Laminar Blood Flow 
The behaviour of blood flow throughout most of the circulatory system is termed laminar 
flow. It is distinguished by concentric layers of blood moving at different velocities in 
parallel down the length of a blood vessel. Basically, laminar flow is defined as when a 
fluid flows in parallel levels, with no distraction between the levels. The peak velocity 
(Vmax) is located in the center of the vessel and the lowest velocity (V=0) is seen along the 
vessel wall 7.  
1.6 Poiseuille’s Law 
Poiseuille’s law is a physical law that states that the velocity of a liquid flowing through a 
capillary is directly proportional to the pressure of the liquid and the fourth power of the 
radius of the capillary and is inversely proportional to the viscosity of the liquid and the 
length of the capillary. 
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The formula below, known as Poiseuille’s law, can be derived by integrating the velocities 
of all the concentric rings of flowing blood and multiplying them by the areas of the rings: 
𝑸 = 𝝅∆𝑷𝒓𝟒𝟖𝜼𝒍  
In which Q is the rate of blood flow, ∆P is the pressure difference between the two ends of 
the vessel, r is the radius of the vessel, l is length of the vessel, and η is viscosity of the 
blood 7. Therefore, huge alterations of blood flow can be achieved with small changes of 
vessel diameter. 
1.7 Autoregulation 
Autoregulation is the intrinsic regulation of retinal blood flow, such that a change in the 
arterial blood pressure produces a compensatory change in diameter so that the blood flow 
is kept constant. Autoregulation is defined as “the ability of a vascular bed to maintain 
blood flow to the tissues under conditions of varying perfusion pressure” 9.  
Metabolic autoregulation is the ability to change perfusion in response to altered tissue 
needs 10. For example, when metabolic activity increases blood flow will proportionally 
increase. Autoregulation and metabolic autoregulation represent different mechanisms 
involved in the overall regulation of retinal blood flow. 
1.8 Quantification of Retinal Blood Flow 
The methods for measuring retinal blood flow have improved but still require further 
development.  Some of these methodologies are described briefly here.  
Previous techniques for assessing retinal perfusion have several restrictions, such as being 
invasive (e.g. Fluorescein angiography), or are subjective (e.g. Blue field entoptic 
phenomenon), or are incapable of calculating blood flow (e.g. Retinal Vessel Analyzer) 
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since a surrogate factor of flow is actually measured. Furthermore, the Canon Laser Blood 
Flowmeter is an instrument that utilizes bi-directional laser Doppler velocimetry and 
simultaneous vessel densitometry to determine volumetric retinal blood flow and is 
currently restricted to relatively large vessels (>60µm) and a single measurement site.   
Fourier-Domain optical coherence tomography (FD-OCT) is a non-contact imaging method 
that mixes micrometer-scale resolution with millimeter image penetration depth 11-13. It is 
similar to the ultra sound technique with the exception of using light energy in the form of 
laser instead of sound. FD-OCT is based on low coherence interferometry, a classic optical 
measurement technique. FD-OCT makes high-resolution imaging possible. It is clinically 
used in the diagnosis and management of retinal diseases. 
To overcome some the previous limitations of retinal blood flow measurements, a new 
prototype termed Doppler FD-OCT blood flow (e.g. Optovue RTVue) has been developed. 
Doppler FD-OCT measures the intensity of light back-reflected from various features 
within the imaged object resulting from spatial variations of the tissue refractive index and 
then detects the Doppler signal in each point within the object 14, 15. 
Another OCT based technology, termed bi-directional OCT, has been designed to measure 
retinal blood flow independent from the angle of incidence 16. This is based on the 
illumination of a retinal vessel by two lasers from two different angles (α1 and α2), 
separated by a known angle Δα 17. 
1.9 Retinal Blood Oxygen Saturation  
A critical aspect of the circulation is the overall oxygen delivery to the tissues.  
Measurement of oxygen in the blood (SO2) is called oximetry; in other words, oximetry is a 
technique in which the blood oxygen saturation level is quantified. A constant supply of 
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oxygen to the retina is required and this demand is regulated primarily by the choroidal 
blood vessels 1,2,18 and to a lesser extent by the inner retinal vessels. Serious pathological 
conditions arise when this supply is disturbed. For example, the major hallmarks of 
proliferative diabetic retinopathy (e.g. retinal neovascularization and macular edema) are 
thought to partly result from hypoxia and defective vascular autoregulation 19,20. Therefore, 
it is critical to study the regulation of oxygen supply to the retina in order to learn more 
about the pathophysiology of diseases such as diabetes and age-related macular 
degeneration.  
The combination of retinal oxygen saturation and retinal blood flow can be used to extract 
more information about retinal metabolism since:  
Retinal O2 Delivery = [1.39 x Hb x SaO2 + (0.003 x PaO2)] x blood flow 
Theoretically, each gram of Hemoglobin binds 1.39 ml of oxygen. The oxygen saturation 
curve represents a PaO2 (arterial oxygen tension) as a function of SaO2 (Arterial SO2). The 
hemoglobin concentration is calculated by production, destruction and loss. 0.003 stands 
for the oxygen solubility coefficient in human plasma 21. 
There are some methods that simultaneously measure retinal blood SO2 and retinal blood 
flow measurements, which are restricted to animals.  
1.10 Quantification of Blood Oxygen Saturation (Oximetry) 
1.10.1 Oxygen Transport 
Oxygen is one of the most required substrates in virtually all tissues. Oxygen diffuses into 
the pulmonary blood in the lung’s alveoli and then will be transported to the tissues. 
Haemoglobin is responsible for carrying almost all of the oxygen in the blood. It is 
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composed of four subunits; each accompanied with a haeme group plus a globin chain. The 
heme group is composed of a porphyrin ring that contains an iron (Fe) atom in its center. 
Typically, the Fe is in the +2 redox state (ferrous) and can reversibly bind oxygen 22. 
1.10.2 Pulse Oximeter Principle 
Pulse oximetry is a non-invasive technique to measure the oxygen saturation in arterial 
blood. Pulse oximetry is based on the different absorption characteristics of 
oxyhaemoglobin (HbO2) and deoxyhaemoglobin (Hb) for red and infrared light 23. A pulse 
oximeter is based on spectral analysis and brings together two technologies, 
spectrophotometry (a technique which measures haemoglobin oxygen saturation) and 
optical plethysmography (a technique which measures changes in pulsatile of arterial 
blood volume where the sensor is located) 23.  
1.10.3 Cerebral Oximetry 
Similar technology to pulse oximetry applies for cerebral oximetry in that it uses different 
light absorption between oxygenated and deoxygenated hemoglobin to quantify oxygen 
saturation (650–900nm) 24. Cerebral oximeters release consecutively pulsed near-infrared 
light that is capable of penetrating the skull, and detect photons reflected back through the 
skull to define oxygen saturation. It represents a balance between oxygen delivery and 
consumption of the brain. 
1.10.4 Retinal Oximetry 
The ocular fundus provides a direct view of retinal vessels. Imaging these vessels can 
deliver information on retinal morphology, retinal blood flow and even blood oxygen 
saturation. Retinal blood oxygen saturation might be associated with metabolic changes in 
ocular diseases. The notion of retinal oximetry has been acknowledged since the 18th 
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century. Attempts to non-invasively measure the retinal blood oxygen saturation date back 
to the 1950's. Different retinal oximetry techniques are described in the literature, the 
primary ones are: photographic, digital and spectroscopy methods. Each method has its 
advantages and disadvantages. Generally, the techniques used to study retinal oxygen 
saturation can be divided into invasive and non-invasive methods. Invasive measurements 
are defined as techniques that involve penetration to the body (probe insertion, dye 
injection).   
1.10.4.1 Invasive Measurements of Oxygen Saturation 
Generally two types of probes exist: oxygen sensitive polarographic electrodes and probes 
containing oxygen sensitive dye.  
The electrode method is established on the basis of an electrochemical reaction. This 
reaction involves oxygen as a substrate.  This is achieved by using a polarising voltage 
across the two electrodes. The reaction rate correlates with the concentration of dissolved 
oxygen in the vicinity of the electrodes and a current 25-29.  
The other generation of the probes holds an oxygen sensitive dye, palladium-mesotetra-(4-
carboxyphenyl)-porphyrin. The dye is excited by specific wavelength light and then re-
radiates light with a different wavelength, which can be detected. The reradiated light is 
influenced by the concentration of oxygen 30-32. 
Another invasive technique exists which is based on injecting an oxygen sensitive dye into 
the blood stream instead of adhering the dye to the optic probe and inserting it to the eye. 
The injected dye will reach the retinal and choroidal vasculature as well as the rest of the 
vasculature in the body. Subsequently the retina and the choroid will be illuminated with a 
specific wavelength light and the reemitted light will have the information on the oxygen 
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concentration in the vicinity of the dye. Unfortunately, this technique is not safe to be used 
for human retina since the dye in not risk-free (e.g. toxicity). Several studies have used 
oxygen sensitive techniques 33-36 but their use is confined to patients who are undergoing 
surgery (e.g. vitrectomy). Generally, the invasive techniques are either limited to animal 
studies or patients with a restricted population. However, these studies contributed a wealth 
of information on retinal and choroidal oxygenation, mainly operating on animal models, in 
health and ocular diseases.  
1.10.4.2 Non-invasive Measurements of Oxygen Saturation  
Haemoglobin Contribution in Oxygen Saturation Measurement 
Non-invasive retinal oximetry demands an imaging system, which captures retinal images 
at multiple wavelengths of light. Retinal non-invasive measurements of oxygen saturation 
are based on measurements of haemoglobin color / absorbance. This makes it compulsory 
to study the key characteristics of haemoglobin and oxygen transportation in blood. 
Oxygen is transported in the blood either bound to haemoglobin or dissolved in the plasma 
(9 mmol of oxygen is carried by binding to haemoglobin in each liter of arterial blood and 
about 0.1mmol/L is dissolved in plasma considering haemoglobin concentration is 150g/L, 
assuming standard pH) 37.  The percentage of dissolved oxygen is insignificant in both 
arterial and venous blood. Therefore measuring the magnitude of oxygen bound to 
haemoglobin could be a useful assessment of the oxygen content in blood in the retina. 
Oxygen saturation is usually defined as the proportion of haemoglobin that is bound to 
oxygen.  
 [ ]
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[HbO2] is the concentration of oxygenated haemoglobin and [Hb] is the concentration of 
deoxyhaemoglobin 
Haemoglobin Light Absorbance 
As mentioned above, non-invasive oxygen saturation measurements are based upon the 
absorbance of haemoglobin. Oxygenated and deoxygenated haemoglobin represent 
different absorbance properties.  
 
Figure 1.1 This graph represents absorption spectra of Hb and HbO2. 38 Reprinted by permission from 
Macmillan Publishers Ltd: [Eye] 38, copyright 2011.  
 
Light absorption of oxygenated and deoxygenated haemoglobin is different at most 
wavelengths of light. Although as can be seen in the above figure (Figure 1.1), the 
absorption of light in oxy- and deoxyhemoglubin is the same at certain wavelengths, and 
these are termed isosbestic wavelengths.  
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Light Absorbance Assessment 
Light absorbance of a solution can be described with optical density; and optical density is 
defined as: 
 
OD is optical density  
I0 is the original light intensity before reduction of light due to absorbance  
I is the light intensity after absorbance in the sample / solution has weakened the light 
intensity. 
Looking at the optical density equation, it can be concluded that a greater optical density 
results in greater absorbance. A blood vessel optical density measured at an isosbestic 
(oxygen insensitive) wavelength will be related to vessel diameter and other factors but not 
oxygen saturation. Also, optical density at a non-isosbestic wavelength (oxygen sensitive) 
will rely on similar factors as the optical density at an isosbestic wavelength but also on 
oxygen saturation. Therefore the ratio optical densities at a non-isosbestic and isosbestic 
wavelength will be sensitive to oxygen saturation while the influence of other factors such 
as vessel diameter will neutralise. Several studies 39,40 showed that for a solution of 
haemoglobin in water there is a roughly linear relationship between such ratio and oxygen 
saturation; 
 
Where a and b are constant and ODR is the ratio of optical densities. 
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It is more difficult to measure blood in retinal vessels than a solution of haemoglobin in a 
test tube. The above equation is imprecise as the light is scattered from blood cells and 
vessel walls 41-45. Moreover, the light intensities, I and I0 have to be assessed from reflected 
light rather than transmitted light and the differences in pigmentation in the retina (within 
and between subjects) can affect the measurement 39,41. 
The light intensity is estimated by the brightness assessment on the vessel. This brightness 
is influenced by light absorbance by blood in the vessel. I0, the reference light intensity, is 
estimated by the brightness of the image next to the vessel. Using brightness near the vessel 
for reference (I0), the light intensities I and I0, are influenced by comparable factors apart 
from light absorbance by the vessel.  
1.10.4.2.1 Dual-Wavelength Retinal Oximetry  
Hickam and Frayser were the first to noninvasively measure the retinal oxygenation in 
human using photographic methods by using particular filters to acquire fundus images 
with two wavelengths of light 40,46. Laing and co-workers followed their work and 
established two-wavelength photographic densitometry to obtain oxygen saturation in 
retinal vessels in rabbits 47. This technique is restricted due to its laborious nature. It is 
fundamentally restricted by the nonlinearity and inconstant reproducibility of photographic 
film. 
Beach and co-workers introduced another version of two wavelengths to measure oxygen 
saturation 39. The key difference was the use of digital camera technology and optical 
solutions that was not used by Hickam. Beach and co-workers also tried to compensate for 
the eye movement by capturing both images (one with a wavelength sensitive to oxygen 
saturation and one insensitive) at the same time and with a single flash. They also tried to 
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eliminate the effect of vessel diameter and fundus pigmentation.  Hardarson and co-
workers used a technology based on the technology of Beach and co-workers. They 
improved the computer programs, which made it more repeatable 48. Hammer and co-
workers also developed an instrument, which uses two wavelengths of light simultaneously 
but using a different optical approach 49,50.  
1.10.4.2.2 Three-Wavelength Retinal Oximetry 
An instrument that utilised the scanning of three wavelengths and the detection of reflected 
light electronically was built to compensate for the effect of light scatter. The technique 
uses scanning fundus reflectometry to calculate the optical density of a retinal vessel at 
three wavelengths (558, 569, and 686 nm). A vessel tracking system was used to reduce the 
effects of eye movements during scanning 42. One of the drawbacks of this method is that it 
only measures a small retinal area at a time. Later, another scanning technique was 
introduced with four wavelengths 51. 
1.10.4.2.3 Multi-Wavelength Retinal Oximetry 
It is difficult to obtain absolute oxygen saturation because of the approximation made in 
two-wavelength oximetry. The result of two-wavelength oximeters might rely on factors 
such as vessel diameter and fundus pigmentation. Some groups attempted to measure 
absolute retinal oxygen saturation with more wavelengths and different modelling to 
estimate the saturation from light intensities. Some of these techniques are challenged by 
long exposure time and therefore limited to immobilized eyes in animal studies.  
The simultaneous capture of light at multiple wavelengths (less than 2nm apart over a 
range of several hundred nanometres) was performed by coupling an imaging spectrograph 
with a fundus camera 52,53. This method might produce absolute values but it is restricted to 
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only a slit of 1.5 mm x 40 μm at a time. This permits simultaneous assessment of a retinal 
arteriole and venule if they are close together. The retina of patients with central retinal 
vein occlusion was illuminated by bright light for six seconds and separated multiple 
wavelengths with interferometry 54. The method is thought to produce oxygen saturation in 
every pixel of a 35° fundus image. Later, a hyperspectral system with a spectral resolution 
of 2.5 nm and a range of 410 nm to 950 nm was used 55,56. Measurements were acquired at 
the optic nerve head of monkeys and each scan took eight seconds.  
Acquiring information on multiple wavelengths in a short time is challenging because of 
not exceeding safe light levels. However, reducing the area of measurement can solve this. 
Schweitzer and co-workers 53 achieved this by measuring only a slit at the fundus.  
A lens-let array and different filters behind each lens-let has been used by Ramella-Roman 
and co-workers 57. This makes it possible to simultaneously capture an image at several 
different wavelengths. An instrument that captures information on eight wavelengths 
simultaneously by using spectral demultiplexing was established by Harvey and co-
workers (2005) 58.  
Soon after, the multi- / hyper-spectral retinal oximetry approach was performed using a 
technique based upon a hologram of up to 50 distinct wavelengths in snapshot images 59. 
This technique has been mostly limited to animal models.  
1.10.4.2.4 Hyperspectral Approach 
Spectral retinal imaging is a fairly new technique that combines the capabilities of 
spectroscopy and imaging. Spectroscopy is a well-established tool used to investigate and 
analyze materials by means of obtaining and finding the spectral signatures of their 
elements using various combinations or sequences of wavelengths. Spectral imaging 
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expands the efficacy of spectroscopy benefiting both spectroscopy and imaging, thus 
offering both spectral and spatial communication. A stack of monochromatic images is 
projected onto a two-dimensional detector array, such as a charge-coupled device (CCD); 
the data are filed and multiple images are gathered over multiple wavelengths forming a 
“spectral data cube” 60,61.  
At present, conventional imaging techniques provide a digital camera (e.g. CCD) to record 
data. A multispectral or hyperspectral imaging system is capable of generating a reflectance 
or transmission spectrum of each pixel within the image allowing the identification of 
substances by recognizing its corresponding spectral signature. The spectral imaging 
system is principally reliant on a combination of its spectral and spatial resolution. 
A more detailed pixel spectrum is delivered with hyperspectral imaging compared to a 
multispectral pixel spectrum. Consequently, this detailed spectrum allows more 
information to be acquired for accurate classification and quantification. The accuracy of 
the spectral analysis is affected by the higher spatial resolution. Generally, hyperspectral 
imaging of the retina enables direct and quantitative mapping of retinal biochemistry. 
1.10.4.2.4.1 Hyperspectral Retinal Camera (HRC), Optina Inc. 
A prototype custom-built fundus camera (H-8.5 HR Camera, Optina, QC, Canada) is the 
foundation of the hyperspectral imaging system that incorporates a tunable laser source 
(TLS) as the light source. The TLS makes it possible to transfer wavelengths within a 
spectral range of 400-1000nm (visible to IR) and with a half peak bandwidth of 2nm. The 
TLS is built on Photon etc’s Bragg grating filtering technology which permits rapid 
wavelength presentation from the steady and powerful super-continuum light source 
(Leukos-SM-30-OEM, Leukos Innovative Optical Systems, Limoges, France). The TLS 
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can be electronically tuned with an operating ambient temperature of 10-30°C. An 
automatic spectral system is incorporated into the system to achieve exact and accurate 
(<1nm) wavelength choice. The sensitive 1.3MPixel (1392 x 1040 pixel) 14 bit CCD 
camera (Pixelfly USB, PCO AG, Kelheim, Germany) used in this system is for high 
definition imaging.  The imaging system is operated by using PhySpec (Photon Etc, 
Montreal, QC, Canada), a software programme that manipulates the Bragg tunable filter 
(BTF) and CCD camera to allow aspects such as operator defined wavelength range and 
wavelength interval. A low power white light source (delivering about 100mW over 420nm 
to 2400nm) and the BTF are used to exclude the use of conventional flash lamp, and 
therefore all images are acquired at low light levels, thereby minimizing any potential 
change of the metabolites and photopigment status in the eye. A diagonal field of view of 
approximately 37.4° is sustained by the opto-mechanics of the system (Personal 
Communication, Dr Jean-Philippe Sylvestre, 2013) 62. 
1.11 Methods Used to Measure Oxygen Saturation in Diabetic Retinopathy (DR) 
Tiedeman and co-workers 63 used a dual wavelength retinal imaging system in diabetic 
subjects without clinical evidence of diabetic retinopathy during normoglycaemia and 
hyperglycaemia. They reported evidence of significantly higher retinal oxygen 
consumption during hyperglycemia. Hammer and co-workers showed higher venular 
oxygen saturation with the severity of diabetic retinopathy in subjects with mild non-
proliferative DR and in subjects with proliferative DR 41. An insignificant increase in 
retinal oxygen saturation was also reported comparing healthy controls to non-proliferative 
diabetic retinopathy subjects, though significance was only reported for severe- non-
proliferative diabetic retinopathy and proliferative DR 56. This suggests that imaging 
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techniques such as hyperspectral retinal imaging may provide improved methods of 
predicting the probability of onset, differentiating the severity and of observing progression 
of diabetic retinopathy in vivo. A recent study by Man and co-workers 64 suggested that 
eyes with longer axial length show lower retinal function and hence lower O2 consumption; 
therefore eyes with longer axial length are fairly less hypoxic when diabetes exists, which 
may partly explain the reduced risk of DR in these eyes. Hardarson also reported increased 
retinal blood oxygen saturation in patients with diabetic retinopathy 65. 
1.12 Advantage and Disadvantage of Non-invasive Retinal Oximetery Techniques 
The first methods introduced by Hickam used photographic densitometry of large retinal 
vessels in vivo to monitor arterial and venous retinal blood oxygen saturation 40. This 
method depended on external calibration by means of independent arterial oxygen 
saturation measurement. This technique is laborious and restricted by the nonlinearity and 
variable reproducibility of photographic film.39  
Delori established a retinal oximetry technique based on retinal photoelectronic 
measurements of optical density at three wavelengths. A mechanical scanner in a modified 
fundus camera equipped with a photomultiplier detector to sequentially monitor the light 
reflected inside and outside vessels at three wavelengths was used. This method could 
compensate for the effect of light scatter and minimize the eye movements during 
scanning. However, this technique was limited by measuring a small area at a time. The 
multi-wavelength oximeter introduced by Oxymap (Reykkavik, Iceland) has the advantage 
of measuring a larger area and little expertise to acquire pseudo-color fundus image of 
retinal vessel oxygenation. The disadvantage of this method is that they used a flashlight 
that can in turn cause metabolic / photochemical changes in the retina. Flash intensity 
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significantly affects retinal vessel oxygen saturation measurements using dual-wavelength 
retinal oximetry 66. In terms of retinal oxygen saturation imaging, the technology provided 
by Optina Inc (previously Photon etc) permits the acquisition of hyperspectral retinal 
images for numerous wavelengths in a fraction of a second (i.e. minimizing eye movement 
effects) at background light levels (BTF) far lower than any of the competing technologies, 
thereby avoiding disturbance of retinal metabolic status. 
The other drawback of the Oxymap oximeter is that it can only give relative oximetry 
values and this explains why sometimes the reported values are over 100%. However, it 
has been reported that the results are repeatable and sensitive to changes in oxygen 
saturation. The best interpretation of the results would be the oxygen saturation is probably 
slightly higher in diabetic patients than normal 67.  
1.13 Extraneous Factors Affecting Retinal Oximetry Results 
To date, no technique has been definitively able to quantify retinal blood oxygen saturation 
independent of vessel diameter, haemoglobin concentration, and fundus pigmentation. One 
of the puzzling characteristics of whole-blood spectroscopic oximetry techniques is the 
scattering of light. The refractive-index discontinuity between red blood cells and the 
plasma in which they are suspended causes light scattering 43,68.  
Two optical spectroscopic techniques have been introduced to determine the retinal oxygen 
saturation. One method illuminates an area of the retina and the retinal images are formed 
on film or a CCD detector array. The other method scans multiple monochromatic beams 
across a retinal vessel. The light that reflects back out of the eye is collected at distinct 
points along the scan. Both methods are similar in that the reflected light from the center of 
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the vessel is compared with the reflected light from the fundus on each side of the vessel to 
calculate the transmittance of the blood within the vessel.  
Generally, a beam of light passes through the pupil of the eye and is focused onto a retinal 
vessel. Then the fraction of light that is reflected back out of the pupil of the eye is 
collected by retinal oximeter. There are several light paths that influence this collected 
power. Some quantity of the incident light may be directly backscattered from the cornea, 
lens or vitreous. Also, there is a specular reflection from the apex of the vessel. This 
reflection may derive from the inner limiting membrane 69 or from the vessel wall. The 
beam flux decreases according to the Lambert–Beer Law due to the differential light 
absorption by hemoglobin and oxy-hemoglobin within the red blood cells contained in the 
vessel. Light is also backscattered by red blood cells. A portion of this scattered light is 
distributed at angles that cannot be collected by the instrument and this unquantified 
scattered light component results in an apparent rise in absorption. The beam that emerges 
from the other side of the vessel is amplified due to scattering and attenuation of 
absorption. The beam passes through the retinal rods and cones and ultimately reaches the 
scattering and also absorbing layers of the retinal pigment epithelium and choroidal plexus 
70. Strong melanin and hemoglobin absorption restricts lateral diffusion and causes a tight 
localized point spread function on the retinal pigment epithelium for visible wavelengths 
shorter than 575 nm. For wavelengths above 575 nm, the light enters the choroid deeply 
and reflects off the sclera and scatters back through the choroid 71. Concerning retinal 
oxygen saturation imaging, the conventional flash used to adequately illuminate the fundus 
will change the metabolites and photopigments of the retina.  
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There are also other technical problems associated with the oximetry techniques such as 
poor image quality as a result of small vessel branches and haemorrhages. The oximeters 
can only quantity large first or second-degree vessels reliably (> 50 μm diameter) and 
vessel diameter may disturb the outcomes. Haemorrhages close to the measured vessel 
segment can also affect the results of the measurement by affecting the measured 
brightness, used as a reference in the saturation calculation.  
1.14 Clinical Applications of Retinal Oximetry  
Accumulating evidence suggests that vascular dysfunction plays a role in several prominent 
ophthalmic diseases such as diabetic retinopathy, glaucoma, etc. These studies provide data 
on ocular blood flow using a relatively small number of complicated ocular blood flow 
imaging techniques.  Although these techniques are not used clinically, they can potentially 
offer the earlier detection of ocular diseases and possibly be utilized to sensitively monitor 
new therapeutic strategies.  
Clinically, retinal oxygen saturation can be used in the early detection of changes in 
autoregulation 7 and blood flow in the retina that have been linked to the onset of diabetic 
retinopathy (DR). Reduced oxygenation and the subsequent abnormal angiogenesis results 
in loss of retinal tissue and resulting vision impairment 72. Another useful application of 
retinal oxygen saturation is the assessment of central venous oxygen saturation as an 
indicator of oxygen delivery to vital organs such as the brain 73. There are invasive 
procedures for monitoring oxygen delivery, for instance fiber optic sensors inserted into the 
heart and pulmonary artery 74, they can be used in a hospital environment but they are not 
suitable for ambulatory medical care. Therefore, the eye could be the ideal candidate as a 
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window to the body and the retina for monitoring blood oxygen levels since retinal vessels 
are easily accessible and readily imaged.  
1.15 Review of Diabetes  
Diabetes is a metabolic disorder of multiple etiologies considered as a persistent 
hyperglycemia resulting from defects of insulin secretion, insulin action or both 73. There 
are two main types of diabetes: are type 1 (10% of individuals; categorized by autoimmune 
destruction of Islet cells) and type 2 (90% of individuals; categorized by insulin resistance 
and / or reduced insulin secretion) 76.  
1.15.1 Complications of Diabetes 
Diabetes is often accompanied by several complications that share the same aetiology and a 
major of these complications is vascular related. The Diabetes Control and Complications 
Trial and United Kingdom Prospective Diabetes Study acknowledged chronic 
hyperglycemia as an initiating cause in the complications presented in diabetes that 
influence the retina, kidneys, nerves that result in myocardial infarction and cerebro-
vascular accident. Both macro- and micro- vascular complications of diabetes are 
decreased when rigorous control of blood glucose is maintained 77,78. 
1.15.2 Retinal Blood Flow in Diabetic Retinopathy  
Even though hyperglycemia is thought to be the initial insult in the pathogenesis of DR 79, 
the effects on hemodynamic parameters should not be underestimated in the development 
of DR. Retinal blood flow impairment is one of the earliest functional abnormalities 
detected in diabetes 80,81.  
The notion of altered retinal blood flow in diabetes is not new80. Many studies have been 
dedicated to assess retinal hemodynamics. The commencement of clinical signs of evident 
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DR has been proposed to take place after retinal vasodilation. Elevated retinal blood flow 
has been classically proposed to ultimately cause the progress of DR, probably because of 
amplified frictional forces (i.e., shear stress) on the endothelial cells lining the walls of 
retinal vessels 81. However, the exact nature of the blood flow disruption is debatable, 
perhaps due to the variety of methods used to measure retinal hemodynamics, the diverse 
stages of retinopathy considered, and the diversity of the diabetic groups 82. From a clinical 
perspective, the assessment of ocular hemodynamics requires an earlier detection of DR 
and improved DR severity differentiation and perhaps a flag for new treatment 
opportunities. Retinal hypoxia is thought to promote the production of vascular endothelial 
growth factor (VEGF) and the development of macular edema and neovascularization. 
Measurement of retinal oxygenation in patients with diabetes may help to assess the 
severity of DR and the response to novel “prophylactic” treatments. Ultimately, knowing 
the blood flow to, and the oxygenation of, the retinal tissue will permit the assessment a 
metabolic parameter of the retinal tissue, namely oxygen utilization (also termed “retinal 
oxygen delivery”). 
1.15.2 Vascular Reactivity (VR) in DR 
VR characterizes the hemodynamic response of the vasculature to a stimulus, such as 
hyperoxia or hypercapnia 83. VR has been reported to be impaired in response to hyperoxia 
with simultaneous hyperglycemia 84,85. However, another study has shown that 
hyperglycemia has no effect on hyperoxia induced retinal vascular reactivity 86-88. 
1.15.3 Retinal Responses to Flicker in DR 
While the particular mechanism behind flicker-induced vasodilatation is still controversial, 
it has been used to test the ability of retinal vessels to adjust to different metabolic 
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circumstances in health and disease. Garhöfer and co-workers showed that flicker 
responses of retinal arterioles and venules are significantly decreased in patients with 
diabetes with no or mild NPDR 89. More recently a study by Lasta and co-workers 
confirmed the previous study in type 1 diabetes with no or mild NPDR 90.  
1.15.3 Retinal Oxygen Saturation in DR  
It has been suggested that a change in blood circulation leads to functional damage and 
broad retinal tissue impairment and disturbance during diseases such as DR 42. In this 
respect, it will be critical to study the oxygen distribution or consumption of the retina and 
its alteration in response to DR since RBF or SO2 alone represent only part of the required 
information to calculate retinal oxygen utilization. Measurement of these alterations could 
be used to improve the capability of early detection of diseases such as diabetes / diabetic 
retinopathy. Most of the non-invasive optical techniques that are used to measure the 
retinal oxygen saturation rely on measuring differences between hemoglobin and 
oxygenated hemoglobin (Hb and HbO2) light absorption (see Section procedures for 
complete methodology explanation). Simultaneous retinal blood flow measurement and 
retinal hemoglobin oxygenation are required to assess absolute values of oxygen delivered 
to the retina 45,49. The non-invasive quantification of oxygenation of the retina will be 
feasible by retinal oximetry, which in turn may offer a sensitive and predictive biomarker. 
Quantification of blood flow and oxygenation of the retina will permit the assessment of 
the tissue oxygen utilization. 
Assessing oxygen concentration in the retina has been achieved using O2-sensitive 
microelectrodes introduced into the eye 91-94. While this technique is precise and can 
accurately define oxygen saturation, the invasive nature of the technique limits its’ usage to 
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animal models and disqualifies it from clinical purpose. Alternative methods using the 
introduction of a phosphorescent dye has been utilized to derive oxygen concentration in 
the optic nerve head and retinal vessels 93-95. Nonetheless, the use of such a dye in humans 
is not accepted due to toxicity concerns. Imaging techniques established on oxygenated 
hemoglobin and reduced hemoglobin (i.e. deoxyhemoglobin) and their spectral changes 
have been used in humans to non-invasively assess oxygen saturation in retinal vessels 
39,42,46,52,53,63. Hickam and co-workers first proposed a non-invasive measurement of the 
retinal oxygen saturation using a two-wavelength (510, 640 nm) method. Following that, 
another two-wavelength (470, 515 nm) technique was developed to measure oxygen 
saturation. These photographic based techniques, however, were laborious. Later, Pittman 
and Duling 45 introduced a three-wavelength spectrophotometer method for oximetry. 
Delori introduced the first scanning retinal oximeter illuminating with multiple 
wavelengths 42. Another group 53 used a grating spectrograph to acquire spectra and applied 
a multi-wavelength curve fitting technique for saturation estimation.  Assessment of 
oxygenation in the retina may facilitate the early detection of diabetic retinopathy. Oxygen 
saturation in retinal vessels has been found to be greater in diabetic retinopathy in contrast 
to control subjects 67. A study by Man and co-workers using the oximetry module of the 
Vesselmap system (Imedos UG, Jena, Germany) showed an association between eyes with 
DR and increased venular SO2 and decreased A-V difference in the DR group when 
compared with eyes without DR, suggesting an altered metabolic state in DR 96. Another 
study by Jørgensen and co-workers showed increased SO2 in arterioles and venules and a 
normal A-V difference in PDR patients. They also showed that immediately after retinal 
photocoagulation treatment, the SO2 increases in venules but not in arterioles resulting in 
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the A-V difference decrease when compared to pre-treatment; however, they showed that 
three months after retinal photocoagulation treatment, the SO2 is elevated in arterioles and 
venules but the A-V difference stays the same as the pre-treatment level 97.  
1.15.4 Clinical Classification and Etiology of DR 
DR is a potential blinding disease. It has a vaso-obliteration phase, which eventually can 
result in proliferative phase. DR is categorized as non-proliferative (including: 
microaneurysms, exudate, capillary nonperfusion, permeability or leakage) which leads to 
hypoxia and the final phase as proliferative retinopathy (preretinal neovascularization). Its 
classification is traditionally established on ophthalmoscopically visible signs of increasing 
severity graded from no retinopathy through different steps of non-proliferative or pre- 
proliferative disease to advanced proliferative disease. 
1.16 Retinal Biochemical/Morphological Changes Associated with Hyperglycemia 
1.16.1 Inflammatory Biochemical Biomarkers  
1.16.1.1 Vascular Endothelial Growth Factor (VEGF) 
Normal retinal vascular development appears not to be determined by hypoxia-induced 
VEGF expression 98. However, VEGF signaling is critical for the development of normal 
vasculature 99. VEGF is a well-known persuasive angiogenic factor that stimulates retinal 
neovascularization, leading to tractional retinal detachment and vitreous hemorrhage, 
which are important because they represent the most severe causes of visual loss in patients 
with PDR 100,101. There is a wealth of evidence that during retinal and choroidal 
neovascularization and the formation of diabetic macular edema, hypoxia intensely 
stimulates VEGF expression by stabilization of HIF-1 (hypoxia-inducible factor-1) 
transcription 102-104. 
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Previous studies also specify the important role of VEGF in the breakdown of the blood-
retinal barrier in DR. Vascular hyper-permeability secondary to tight junction impairment 
between vascular endothelial cells and neovascularization are bold symbols of vascular 
endothelial cell dysfunction induced by diabetes. VEGF plays an important role to mediate 
these early and late vascular alterations 105-107. It has been reported that VEGF is 
significantly increased in diabetes and a correlation between the levels of VEGF and DR 
severity has been shown101. Angiogenesis is caused by disruption between the production of 
angiogenic activator such as VEGF and angiogenic inhibitors such as angiostatin and 
pigment epithelium-derived factor (PEDF) 108,109. The amplified production of angiogenic 
activators and reduced production of angiogenic inhibitors caused by local hypoxia, 
disturbs the balance between the desirable and undesirable regulators of angiogenesis. 
Subsequently, over proliferation of capillary endothelial cells occurs which leads to 
neovascularisation 109. 
1.16.1.2 Transforming Growth Factor Beta (TGF-β)  
Anomalous interactions between the endothelial cell and pericytes might be implicated in 
diabetic microangiopathy 110. There are some pathways of interaction between the 
endothelial cells and pericytes. One of these communication paths is TGF signaling, which 
is important for pericyte differentiation 111,112. Pericytes make the vasculature stable, 
modulate (rather than majorly control) blood flow at the local tissue level and control 
endothelial proliferation. One of the hallmarks of early changes in diabetic retinopathy is 
pericyte loss 113. Another structural hallmark is thickening of the capillary basement 
membrane. These changes along with others seen in diabetes such as increased blood 
viscosity might result in occlusive angiopathy and a consequent tissue hypoxia. Growth 
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factors such as TGF-β and VEGF might be involved in basement membrane thickening 114.   
 It has been suggested that increase of serum proteins due to microvascular disturbances and 
hypoxia might be a cause for vitreous alterations of Insulin-like growth factor I (IGF-I) and 
of active TGF-β. These changes appear to take place late in the sequence of events 
resulting in PDR and are not restricted to diabetes; they were also detected in other retinal 
hypoxic diseases 115. TGF-β1 has been shown to participate in the pathogenesis DR116,117. A 
role for TGF-β1 has been shown in the microvascular complications of type 1 diabetes 
118,119.  In addition, hyperglycemia induces protein kinase C (PKC) activation, which results 
in increased microvascular protein buildup by up-regulating TGF-β1, fibronectin and type 
IV collagen 120,121. Serum protein influx due to hypoxia is likely the reason for vitreous 
alterations of active TGF-β 115.  
It has been shown that TGF-β appears to decrease the tightness of the inner blood retinal 
barrier (iBRB) 122. A study showed that an intravitreal level of Angiopoietin-2 is 
significantly associated with VEGF and TGF-β1 concentration in DR undergoing 
vitrectomy. This suggests that these factors could be involved in promoting retinal 
angiogenesis synergistically 116.  
1.16.1.3 Angiopoietins-2 (Ang 2) 
Ang 2, one of the important growth factors of hypoxia-induced microvascular changes, is 
significantly involved in the initiation of retinal neovascularization. Angiopoietins binds to 
the receptor tyrosine kinase, Tie2. The angiopoietins are growth factors that regulate the 
development of physiological angiogenesis and pathological neovascularization 123,124. 
Vitreal increase in Ang 2 and VEGF levels as well as a correlation between Ang 2 and 
VEGF has been suggested in PDR 125. Another study proposed that Ang 2 is expressed by 
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hypoxia and VEGF in bovine aortic endothelial cells 126. Another study showed that Ang 2 
is playing a role in pericyte recruitment and preretinal vessel formation under physiological 
and pathological disorders127. There is also evidence that Ang 2 is involved in pericyte 
apoptosis by α3β1 integrin signaling in DR 128. 
Ang 2 has been shown to be elevated in the vitreous of patients with clinically significant 
macular edema (CSME) 129 suggesting a possible role of Ang 2 in the alteration of the 
blood-retinal barrier. Another study suggested that Ang 2 might be involved in elevated 
vasopermeability in DR130.  
1.16.1.4 Leptin 
Leptin, an adipocyte-derived hormone, is an energy metabolism regulator and is associated 
with diabetes mellitus through its metabolic actions. Leptin stimulates endothelial 
proliferation and angiogenesis 131. Results describing the association between serum leptin 
and diabetic microangiopathies are variable. Sari and co-workers 132 didn’t find any 
difference in the leptin levels in serum between patients with and without diabetic 
nephropathy, retinopathy and neuropathy. Furthermore, Asakawa and co-workers 133 
reported no relationship in the leptin level and microangiopathies in Japanese patients of 
type 2 diabetes. However, Freuhwald-Schultes and co-workers 134 reported high serum 
leptin amount in type 2 diabetes patients with early stages of renal disease, (i.e., 
microalbuminuric and macroalbuminuric nephropathy), while serum leptin level did not 
significantly show any association with diabetic neuropathy. Jung and co-workers 135 didn’t 
find any relationship between leptin concentrations and diabetic retinopathy.  
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1.16.1.5 Tumor Necrosis Factor (TNF-α) 
Elevated levels of TNFα have been reported in the vitreous of diabetic patients 136 and a 
robust association between plasma levels of TNF-α and severity of DR has been shown 137. 
Furthermore, increased levels of TNF-α in an animal model of diabetes prompted NADPH 
oxidase and production of reactive oxygen species (ROS) causing endothelial dysfunction 
138 In vivo studies have also shown that TNF-α plays a role in angiogenesis 139. There is also 
evidence that blocking TNF-α reduces leukocyte adhesions as well as ICAM-1 expression 
140. TNF-α-mediated endothelin-1 release and cell proliferation is enhanced by hypoxia in 
human optic nerve head astrocytes in glaucoma 141. 
1.16.1.6 Intercellular Adhesion Molecule-1 (ICAM-1) 
Inflammatory leukocyte recruitment constitutes one of the key pathological stages in DR. 
Diabetes has been shown to up-regulate several pro-inflammatory mediators in the retina, 
such as ICAM-1, and this localized inflammatory process is considered to be part of the 
development of DR 142-145. Retinal vascular ICAM-1 expression is elevated by VEGF. This 
may stimulate retinal leukostasis in diabetic eyes 146. Increased expression of ICAM-1 has 
been demonstrated to show an association with the severity of retinopathy 147. There is also 
a direct relationship between ICAM-1 and VEGF-induced vascular permeability 148, as well 
as evidence that pigment epithelium-derived factor (PEDF) decreases the hypoxia-induced 
ICAM-1 expression 149. 
1.16.1.7 Hepatocyte Growth Factor / Scatter Factor (HGF / SF) 
Complicated events of interactions between retinal cells with growth factors and cytokines, 
extracellular matrix proteins and metallo-proteinases trigger the development of 
proliferative retinal diseases 150-152. HGF is one of these growth factors that have been 
	   31	  
studied. Its receptor is the c-met, a transmembrane tyrosine kinase 153.  An elevated HGF 
level in patients with type 1 diabetes mellitus with PDR and the relationship between 
progression of DR and the concentration of HGF was suggested as a role of HGF in the 
pathogenesis of PDR 154. 
It has been reported that HGF is an endothelium specific growth factor with more potent 
mitogenic activity than that of basic fibroblast growth factor (b-FGF), VEGF, interleukin 6 
(IL-6), and interleukin 1 (IL-1) 155,156. Furthermore, the HGF concentration in the vitreous 
of PDR has been shown to be higher when compared to non-diabetic patients 157. In 
addition, it has been presented that HGF might affect the progression of DR 158. 
1.16.1.8 Heparin-Binding Epidermal Growth Factor (HB-EGF) 
It has been reported that the retinal pigment epithelial (RPE) cells migration can be 
synergistically stimulated by HGF coupled with HB-EGF or EGF, which are mediated by 
an increased activation of protein kinase C and extracellular signal-regulated kinase (ERK) 
phosphorylation 159. 
1.16.1.9 Interleukin-1 β (IL-1 β) 
IL-1β appears to trigger the neuro-inflammatory cascade 160 and is a multifunctional pro-
inflammatory cytokine 161. One of the earliest events after ischemic conditions is IL-1β 
release, which leads to inflammatory response and eventually tissue damage 162. There is a 
growing body of evidence that IL-1β is a retinal damage mediator in DR. IL-1β appears to 
be up-regulated in the retina in experimental diabetes 162-166. More recently, it has been 
reported that IL-1β might up-regulate IL-8 in Müller cells through the p38 mitogen-
activated protein kinases (p38 MAPK) and ERK1/2 pathways 167 (ERK1/2 is a significant 
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member of mitogen-activated protein kinases that control a broad range of cellular 
activities and physiological processes).  
1.16.1.10 Endothelial Growth Factor (EGF) 
It has been reported that the insulin-induced vascular leakage can be prevented by EGF 
inhibition 168. It has been reported that EGF has a potent mitogen role 169. It has been 
reported that AGE could trigger EGF receptor (EGFR) 170,171. The EGRF can bind to 
multiple growth factors such as EGF, HB-EGF 172. ROS might block EGFR 
dephosphorylation 173. 
1.17 Summary 
Retinal blood oxygen saturation could represent a valuable and sensitive biomarker of DR 
potentially prior to any vision loss, although direct evidence to support this statement is 
currently lacking. Current techniques for the assessment of oxygen saturation disturbance 
are limited to the utilisation of only a few specific wavelengths. The oximeter used in this 
study will provide the ability to non-invasively and measures the oxygen saturation of the 
major retinal vessels using multiple wavelengths. The instrument used in this study has the 
capacity to measure full field reflectance for 100s of wavelengths in a matter of seconds 
using a half power bandwidth of only 2nm. This instrument will permit the acquisition of 
high-speed hyperspectral retinal reflection data at background light levels far lower than 
any similar technologies, thereby avoiding disturbance of retinal metabolic status due to 
high ambient light levels. Therefore, it will minimize the influence of eye movements on 
image quality. Retinal oximetry will allow the non-invasive quantification of oxygenation 
of the retina, which in turn may offer a sensitive and predictive non-invasive biomarker. 
Moreover, quantification of blood flow and oxygenation of the retina will permit the 
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assessment of the tissue oxygen utilization. A number of novel inflammatory biomarkers 
predicting onset or progression of retinopathy in patients with type 2 diabetes have been 
identified. Some of these biomarkers such as VEGF, Hb-EGF, HGF, Ang 2, leptin, ICAM-
1, IL-8 and TGF-β, will be investigated in this study.  
To date, VEGF is the most attractive candidate responsible for an early biomarker of DR. 
Elevated blood glucose and retinal hypoxia are both thought to stimulate production of 
VEGF and the development of macular edema and neovascularization within the eye, 
respectively. It has been also shown that ICAM expression is upregulated in the absence of 
oxygen 174. A relationship between oxidative stress and hypoxia has also been shown 175. An 
association between TGF-β and Ang 2 and retinal angiogenesis is thought to exist 116 while 
there are evidence showing that TNF-α is stimulated by hypoxia 141. 
The study of the relationship between inflammatory biomarkers and retinal oxygenation in 
individuals with type 2 diabetes represents fertile scientific ground to be investigated and 
would greatly expand our understanding of the development of DR by defining the 
interaction of inflammatory mediators and retinal oxygen saturation.  
In summary, quantifying retinal blood oxygen saturation could help us better understand 
the pathophysiology behind retinal diseases such as DR and possibly better techniques to 
earlier diagnose of such diseases. 
The combination of retinal oxygen saturation and retinal blood flow can be used to extract 
more information about retinal metabolism since:  
Retinal O2 Delivery = [1.39 x Hb x SaO2 + (0.003 x PaO2)] x blood flow 
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2  Rationale 
The assessment of retinal blood flow is important because its perturbation has been 
suggested to play a role in many ocular diseases such as diabetic retinopathy1-3 and 
glaucoma4-11. Several noninvasive methods have been established to measure ocular blood 
flow in humans. Previous techniques for evaluating retinal perfusion have many 
limitations, such as being invasive (e.g. Fluorescein angiography), or are subjective (e.g. 
Blue field entoptic phenomenon), or are incapable of calculating blood flow (e.g. Retinal 
Vessel Analyzer) since a surrogate parameter of flow is truly measured. To overcome these 
limitations, a new technique termed Doppler spectral Fourier-domain optical coherence 
tomography (Doppler FD-OCT) blood flow (e.g. Optovue RTVue) has been developed. No 
one has properly looked at reproducibility and variability of FD-OCT, there is a need to 
study the reproducibility and variability of FD-OCT. 
DR results in disturbed oxygen delivery to retinal cells, which in turn will cause hypoxia in 
retinal tissue. A relationship between the pathogenesis in DR and retinal hypoxia has been 
found. Hypoxia is thought to provoke neovascularization and retinal edema 12. 
Retinal SO2 could represent a valuable and sensitive biomarker of DR potentially prior to 
any vision loss, although direct evidence to support this statement is currently lacking. 
Current techniques for the assessment of oxygen saturation disturbance are limited to the 
utilisation of only a few specific wavelengths. Ultimately, the retinal oximeter used in this 
study will provide the ability to non-invasively and quantitatively measure the oxygen 
saturation of the blood in the major retinal vessels using multiple wavelengths. However, 
the oximetry data presented in this study is derived from two selective wavelengths in order 
to easily compare and validate my oximetry results with those of other studies, as explained 
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in Beach and co-workers 13. The instrument used in this study has the capacity to measure 
full field reflectance for 100s of wavelengths in a matter of seconds using a half power 
bandwidth of only 2nm and no flash. This instrument permits the acquisition of high-speed 
hyperspectral retinal reflection data at background light levels far lower than any similar 
technologies, thereby avoiding disturbance of retinal metabolic status due to high ambient 
light levels. Therefore, it will minimize the influence of eye movements on image quality 
and will avoid any influence of flash illumination on optical density values. Retinal 
oximetry allows the non-invasive quantification of oxygenation of the retina. 
Quantification of blood flow and oxygenation of the retina will permit the assessment of 
the tissue oxygen utilization, also termed oxygen metabolism.  
A number of novel inflammatory biomarkers predicting onset or progression of retinopathy 
in patients with type 2 diabetes have been identified. Some of these biomarkers such as 
VEGF, ICAM-1, IL-8, TGF-β, Leptin, Angiopoietin 2, EGF, Hb-EGF, and HGF will be 
investigated in this study.  
To date, VEGF is the most attractive candidate biomarker reflecting the severity and 
development of DR. Initially elevated blood glucose and then retinal hypoxia are both 
thought to stimulate production of VEGF and the development of blood retinal barrier 
leakage in the form of macular edema and neovascularization seen clinically as 
proliferative DR. A relationship between oxidative stress and hypoxia has also been shown 
14. An association between TGF-β and Ang 2 and retinal angiogenesis is thought to exist 15 
while TNF-α has been reported to be stimulated by hypoxia 16 .  
The study of the relationship between inflammatory biomarkers and retinal oxygenation in 
individuals with type 2 diabetes represents fertile scientific ground to be investigated and 
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would greatly expand our understanding of the development of DR by defining the 
interaction of inflammatory mediators and retinal oxygen saturation.  
2.1 General Objective 
The general objective of my work was to aid the development of new objective metabolic 
measures and biomarkers of DR and then to apply these outcomes to better understand the 
pathophysiology of DR.  
This study determined the within-session variability and between-session repeatability of 
FD-OCT, an instrument that allows the noninvasive measurement of retinal blood flow. 
The study determined any difference in oxygen saturation and inflammatory vascular 
biomarkers in the aqueous humor in healthy age-matched controls and type 2 diabetic 
patients with mild-to-moderate non-proliferative DR undergoing routine uncomplicated 
cataract extraction. The study investigated the diagnostic value of these early biomarkers to 
distinguish between healthy age-matched controls and type 2 diabetic patients with 
relatively early DR.  
2.2 Specific Aims 
1- The purpose of the first study was to determine the within-session variability and 
between-session repeatability of spectral Fourier-domain optical coherence tomography 
(Doppler FD-OCT) Doppler retinal blood flow measurements in young and elderly 
subjects. 
2- The aim of the second study was to assess oxygen saturation disturbances in the retina 
that occur in patients with type 2 diabetes and to compare the magnitude of retinal SO2 in 
arterioles and venules in healthy age-matched controls and in type 2 patients with relatively 
early (no or mild-to-moderate NPDR).  
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3- The aim of the third study to investigate the relationship between retinal blood flow and 
retinal blood oxygen saturation in NPDR. 
4- The aim of the fourth study was to determine disturbance of vascular biomarkers of 
angiogenesis / inflammation (VEGF, Angiopoietin 2, HB-EGF, HGF, Leptin, EGF, IL-8, 
TGF-β and ICAM-1) in aqueous humor in patients with relatively early DR and in healthy 
age-matched controls.  
5- The aim of the fifth study was to assess the relationship between the retinal oxygen 
saturation and retinal blood flow in order to determine net oxygen values also termed 
oxygen utilization or metabolism (i.e. Retinal O2 Delivery = [1.39 x Hb x SaO2 + (0.003 x 
PO2)] x blood flow). 
2.3 Hypotheses  
1- The FD-OCT will be repeatable in terms of measuring total retinal blood flow. 
2- Disturbance of retinal blood oxygen saturation will occur in relatively early mild-to-
moderate nonproliferative DR in the absence of clinical sight-threatening signs.  
3- There is a direct correlation between retinal blood flow and retinal oxygen saturation. 
4- Disturbance of AH biomarkers will occur in relatively early mild-to-moderate 
nonproliferative DR in the absence of clinical sight-threatening signs. 
5- The relationship between retinal oxygen saturation and vascular biomarkers of 
inflammation will be different between the two groups (NPDR and control).   
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3.1 Introduction  
The human eye is perfused mostly from the ophthalmic artery, the first branch of the 
internal carotid artery. There are two distinct vascular systems that support the mature 
neural retina: the inner retinal vessels and the choroidal vessels. The two beds vary in both 
their embryonic differentiation pattern and functionally in the adult human 1. The retinal 
vasculature is spread mainly within the inner retina and nourishes most inner retinal 
structures. The pigment epithelium and photoreceptors, however, are primarily nourished 
by the choroidal vasculature. The contraction of the arterioles determines the blood flow 
into the inner retinal capillary bed 2. Moreover, the downstream retinal capillaries are 
believed to be able to further fine tune blood flow via the actions of the contractile 
pericytes in response to local tissue demands, such as the level of oxygenation 3. All 
together, these mechanisms sustain constant blood flow over an extensive range of 
perfusion pressures (i.e., autoregulation). 
The assessment of retinal blood flow is important because its perturbation has been 
suggested to play a role in many ocular diseases such as diabetic retinopathy 4-6 and 
glaucoma 7-14. Several techniques have been developed to quantify retinal blood flow in 
humans. Previous techniques for evaluating retinal perfusion have numerous limitations, 
such as being invasive (e.g. Fluorescein angiography), or are subjective (e.g. Blue field 
entoptic phenomenon), or are incapable of calculating blood flow (e.g. Retinal Vessel 
Analyzer) since a surrogate parameter of flow is truly measured.  In addition, a technique 
that truly measures volumetric retinal blood flow, that is bi-directional laser Doppler 
velocimetry and simultaneous vessel densitometry, is currently limited to relatively large 
vessels and a single measurement site.  To overcome these limitations, a new technique 
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termed Doppler spectral Fourier-domain optical coherence tomography (Doppler FD-OCT) 
blood flow (e.g. Optovue RTVue) has been developed. FD-OCT is a non-contact imaging 
method that mixes micrometer-scale resolution with millimeter image penetration depth 15-
17. It is similar to the ultra sound technique with the exception of using light energy in the 
form of laser instead of sound.  FD-OCT measures the intensity of light, back-reflected 
from various features within the imaged object resulting from spatial variations of the 
tissue refractive index. FD-OCT is based on low coherence interferometry, a classic optical 
measurement technique. FD-OCT makes high-resolution imaging possible. It is generally 
used in the diagnosis and management of retinal diseases18,19.  
FD-OCT has the ability to detect motion within a sample from the back reflected light, 
which delivers information on movement 20,21. In respect of terminology, Huang and co-
workers and many other groups have generally used the term “Doppler shift” to describe 
the same phenomenon that other groups describe as a phase shift, or Doppler phase, 
between two subsequent A-scans which represents a difference in position of a given point 
within the waveform between the two scans. From this point forward, we will use the term 
“Doppler phase shift” to describe this phenomenon.  
The variability and repeatability of this new retinal blood flow measurement technique 
needs to be established in order to characterize a significant change and to use it as a 
clinical technique to detect abnormal deviations in blood flow. The aim of this study is to 
investigate the within-session variability and between-session repeatability of the Doppler 
FD-OCT morphologic blood flow technology in young and elderly healthy subjects. 
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3.2 Methods 
3.2.1 Sample 
This study received approval by the University of Waterloo Office of Research Ethics and 
the Research Ethics Board of the University Health Network, University of Toronto, 
Canada. Informed consent was obtained from each subject after explanation of the nature 
and possible consequences of the study according to the tenets of the Declaration of 
Helsinki. The sample consisted of thirty six healthy volunteers in two groups of young and 
elderly subjects. One eye of each of 20 healthy young (mean age 24.7; SD 2.7 years) and 
16 healthy elderly (mean age 64.6; SD 5.1 years) subjects was randomly selected for the 
study. All subjects had a corrected visual acuity of 20/40 or better. Subjects were excluded 
for any ocular or systemic disease, refractive error greater than ± 6.00 DS or ± 2.50 DC, 
glaucoma or diabetes in a first degree relative, history of central nervous system disorders, 
or medications with known effects on blood flow (e.g., anti-convulsants or anti-
inflammatory medications). Subject, and appropriate summary group, characteristics (age, 
gender, and right or left eye, intraocular pressure, and blood pressure) are detailed in Table 
3.1. 
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Young Group 
Name Age M/F IOP Visit 1 Visit 2 Visit 1 Visit 2 Sys Dias Sys Dias 
1 27 F 11.00 10.33 116 68 121 71 
2 24 F 11.33 12.00 115 75 111 74 
3 29 F 12.33 11.33 125 80 121 82 
4 27 F 12.00 12.33 110 69 113 68 
5 28 F 11.00 11.66 97 63 110 64 
6 19 F 15.00 14.00 109 69 100 68 
7 24 F 13.00 12.66 113 67 124 71 
8 26 F 12.66 12.00 106 67 115 73 
9 28 F 11.00 12.00 113 78 102 81 
10 26 F 12.00 11.66 119 81 122 69 
11 22 M 15.00 14.00 128 78 119 69 
12 23 M 14.33 13.66 125 65 111 78 
13 25 M 9.00 10.33 128 71 120 81 
14 26 M 18.33 16.66 128 82 135 87 
15 24 M 13.66 12.33 131 76 129 75 
16 25 M 17.00 15.33 128 67 121 71 
17 20 M 12.00 12.66 129 69 125 73 
18 23 M 13.33 13.00 125 78 119 75 
19 26 M 17.66 16.33 127 81 125 78 
20 22 M 16.00 16.00 129 60 128 61 
Mean 24.7  13.38 13.01 120.05 72.2 118.55 73.45 
SD 2.7  2.48 1.86 9.59 6.69 8.77 6.4 
Elderly Group 
Name Age M/F IOP Visit 1 Visit 2 Visit 1 Visit 2 Sys Dias Sys Dias 
21 64 F 15.00 15.33 145 56 139 59 
22 63 F 13.33 14.00 105 69 111 70 
23 62 F 13.00 15.00 119 84 121 83 
24 62 F 14.00 13.00 136 83 129 86 
25 67 F 15.00 16.00 142 79 134 81 
26 61 F 14.00 13.66 138 83 145 84 
27 68 F 16.00 15.66 133 86 135 85 
28 70 F 11.00 12.00 150 79 145 87 
29 59 F 15.00 14.66 124 78 132 85 
30 78 F 12.66 12.00 124 78 129 75 
31 70 F 14.00 13.33 128 79 135 79 
32 60 M 15.00 14.33 131 72 122 76 
33 60 M 13.33 13.66 120 76 128 75 
34 67 M 14.00 15.33 122 74 124 78 
35 62 M 14.00 13.66 125 79 131 81 
36 60 M 14.00 14.33 128 78 112 73 
Mean 64.6  13.64 13.51 125.58 74.36 123.49 75.72 
SD 5.1  2.00 1.68 12.07 7.21 10.42 7.17 
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Table 3.1 Individual subject / group characteristics for the young and elderly groups. (IOP, intraocular 
pressure (mmHg); Sys, systolic blood pressure (mmHg); Dias, diastolic blood pressure (mmHg); HR, heart 
rate per minute; F, Female; M, Male.) 
 
3.2.2 Doppler Fourier-Domain Optical Coherence Tomography (Doppler FD-OCT) 
Doppler FD-OCT is a novel imaging method that provides in vivo non-invasive assessment 
of retinal structure and also retinal blood flow using a physical phenomenon called Doppler 
phase shift 22. The principle of the Doppler phase shift has been integrated into the 
commercially available Doppler FD-OCT (Optovue Inc, Freemont, CA). Doppler FD-OCT 
generates high resolution cross sectional images of the retina. This instrument utilizes a 
laser light source of 841nm with bandwidth of 49nm with an incident power of 500μW on 
the cornea. Theses parameters result in an axial resolution of 5.4μm in tissue23. System 
transverse resolution was 20μm, as determined by the maximum aperture of the eye24. 
Unlike morphological FD-OCT systems that produce just structural images, the prototype 
Doppler FD-OCT analyzes the Doppler phase shift between two consecutive A-scans. 
Light reflected from moving particles undergoes Doppler phase shift.  
Flow velocity is determined by: 
 
v = ΔΦ. λ!4π.T.n. Sin(θ) 
 
Where v is the flow velocity in an OCT voxel, and ΔΦ=Φ1-Φ2 is the Doppler phase shift. 
Φ1 and Φ2 are the phase of voxels in the same position in consecutive OCT axial scans, λ0 
is the source center wavelength, n is the refractive index of the medium, T is the time 
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interval between consecutive scans and θ is the Doppler angle defined by the OCT beam 
axis relative to the line perpendicular to blood vessel flow axis. 
The maximum detectable Doppler phase shift of 8.9 KHz is determined by the acquisition 
speed of the CCD camera. Given this set up, the maximum measurable velocity in the 
retinal vessels was 2.8 mm/s 24.   
Phase detection caused by retinal blood flow was incorporated into the prototype system by 
creating two circular scans centered on the optic nerve head. The retinal blood flow 
protocol consists of a double circular Doppler scan comprising two concentric rings of 
diameters 3.4 and 3.75 mm centered on the optic nerve head25 (Figure 3.1). The double 
circular FD-OCT beam passes through the pupil nasally with two sets of scans (inferior and 
superior). Two sets of scans are taken to achieve optimum flow measurements from at least 
one of the two sets of scans. The circular scan is displayed as the sinusoidal variation in 
retinal height / morphology (Figure 3.2).  
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Figure 3.1 FD-OCT Doppler image acquisition page. A double circular scan pattern with concentric radii is 
used for the measurement, which is typically centered at the optic nerve head.  
 
 
Figure 3.2 Doppler FD-OCT image for beam passing through the superior nasal quadrant of the pupil. The 
peak of the sinusoidal should be positioned either within superior nasal or inferior nasal quadrants.  
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The incident angle is estimated by vessel center depth difference within the two 
consecutive circular OCT scans from the Doppler FD-OCT images. The measured Doppler 
phase shift, the incident angle calculation and vessel area are used to compute absolute red 
blood cell velocity and retinal blood flow.  
3.2.3 Procedures 
Refraction, logMAR visual acuity, Goldmann applanation tonometry and resting blood 
pressure were assessed prior to dilation of the study eye. The pupil of the study eye was 
dilated using Tropicamide 1% (Alcon, Mississauga, Canada) at the beginning of each visit 
to achieve an adequate view of the fundus for the retinal blood flow image acquisition. 
Visual fields were also tested in subjects using the Humphrey Field Analyzer II (Carl Zeiss 
Meditec, Inc., Dublin, CA) with the 24–2 automated static threshold test. The clinical 
fundus view and the automated perimetry results were all confirmed to be normal. Subjects 
rested for 10 minutes before the start of each study visit to stabilize baseline cardiovascular 
and respiratory parameters. Each subject attended for two visits. The two visits were 
undertaken within two weeks and the second visit was at the same time of day and under 
the same conditions as the initial visit. A minimum of six separate FD-OCT Doppler 
measurements (i.e. each separate measurement comprising an upper nasal pupil scan and a 
lower nasal pupil scan) was acquired at each session.  
3.2.4 Image Grading 
3.2.4.1 Semi-automated Doppler OCT of retinal circulation (DOCTORC) 
Acquired Doppler FD-OCT scans and a SLO en-face image were exported as raw data 
using RTVue Doppler transfer output software. The exported raw data was converted into 
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DOCTORC grading software (version 2.1.1.4) compatible data for image grading and 
retinal blood flow calculation25. After loading the Doppler scan into DOCTORC, the initial 
automated assessment of the loaded scans underwent software processing that identified the 
vessel type based on the Doppler signal characteristics (i.e. arteriole or venule). Grading 
also requires a color fundus image of the optic disc to confirm that the automated vessel 
identification undertaken by DOCTORC is correct by comparing the DOCTORC 
assignment (i.e. venule or arteriole) with that of a color fundus photograph. The Doppler 
scans with 3D OCT image and SLO image were then registered to allow the grader to 
correlate the vessels that are identified on the en-face image with those seen on the cross-
sectional Doppler OCT B-scan. DOCTORC then computed the blood flow from the 
Doppler phase data after manual assessment of scan validity. The blood flow data was then 
automatically exported into the appropriate subject folder.  
The FD-OCT scans were manually graded based on its Doppler signal, size and location 
between inner and outer circle, clarity of the vessel boundary and finally the type of the 
vessel. The grader adjusted the dotted circle in order to make it the same size as the 
Doppler signal (Figure 3.3). There was also a confidence score ranging from 0 to 5 with a 
confidence score guidance sheet (Doheney Eye Institute, CA). The grader of each vessel on 
every scan assigned this score. After completion of all these procedures for all the vessels 
in the Doppler FD-OCT image, the software verified whether the flow calculation for each 
graded vessel was valid. Subsequently, the total retinal venous blood flow was 
automatically computed by summing all calculated flow values from all valid retinal 
venules and the estimated flow from venules25 using an excel file. 
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Figure 3.3 Cross-sectional of retinal blood vessels displaying Doppler signal. The grader adjusts the vessel 
circumference with a dotted circle; and the diameter with a horizontal solid line. 
 
The Co-efficient of Variation (COV) is defined as the ratio of the standard deviation σ to 
the mean μ, such that  𝐶𝑂𝑉 = !!. The Bland-Altman plot26 is a graphical approach to 
compare two measurements methodologies of the same object. The differences between the 
two methods are mapped as the function of the averages of the two. This plot may be used 
to assess the repeatability of a method. The Co-efficient of Repeatability (COR) can be 
calculated as 1.96 times the standard deviation of the differences between the two 
measurements (d2 and d1), such that 𝐶𝑂𝑅 = 1.96 ∗ ! !!!!! !!!! . Repeatability or test-retest 
reliability is defined as the variation in measurements taken by a single operator and 
instrument under the consistent conditions.  
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3.3 Results 
Typically, it takes between 2 to 5 minutes to analyze each vessel. Depending upon a given 
patients vascular tree characteristics, the total time required to undertake the analysis of a 
data set acquired at a single visit varied between 20 to 60 minutes. Box plots of the COVs 
for blood flow in both young and elderly participant groups are displayed in Figure 3.4. 
The individual COVs for blood flow in the young ranged from 0.4 to 20.4% (median 7.5%) 
and for the elderly subjects ranged from 0.6 to 34.6% (median 9.2%). The individual COR 
values for flow ranged from 0.2 to 13.8μl/min (median 4.5μl/min) for young participants 
and from 0.4 to 38.8μl/min (median 9.2μl/min) for elderly participants. 
 
 
Figure 3.4 Box plot of individual COVs for blood flow in young and elderly participants. The error bars 
show the non-outlier range (± 1.5 times the height of the box). 
 
The group mean CORs for retinal blood flow for young participants were 6.4μl/min 
(median 5.9μl/min, relative to a mean effect 39.8μl/min) and for elderly subjects were 
Blood flow 
(Young) 
Blood flow 
(Elderly) 
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10.5μl/min (median 9.2μl/min, relative to a mean effect 46.4μl/min). Difference versus 
mean plots of retinal blood flow (Figures 3.5 & 3.6) revealed two clear outliers in the 
elderly group data (Bland and Altman, 1986). Removal of these outliers reduced the elderly 
group mean COR for blood flow to 9.88μl/min (median 8.3μl/min relative to a mean effect 
42.9μl/min). 
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Figure 3.5 Bland and Altman plot showing the difference in total blood flow as a function of mean blood 
flow between sessions for young subjects. MoD: Mean of Differences; 95% Conf. Limit: 1.96 x SD of the 
MoD (also known as Limits of Agreement). 
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Figure 3.6 Bland and Altman plot showing the difference in total blood flow as a function of mean blood 
flow between sessions for elderly subjects. MoD: Mean of Differences; 95% Conf. Limit: 1.96 x SD of the 
MoD (also known as Limits of Agreement) 
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A scatter plot was used to illustrate test-retest characteristics of the Doppler FD-OCT 
measurement of total retinal blood flow (μl/min) (Figure 3.7). 
 
 
Figure 3.7 Scatter plot illustrating test-retest characteristics of the Doppler FD-OCT for measuring total 
retinal blood flow (μl/min). 
 
The COV values for venous area, velocity and flow can be found in Table 3.2. The COR 
values for both young and elderly subjects has been reported in Table 3.3 and 3.4, 
respectively.  
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Co-efficient of Variation (%) 
 Venous Area Velocity Flow Median Range Median Range Median Range 
Young 4.7 0.8-16.8 10.4 0.1-28.9 7.5 0.4-20.4 
Elderly 4.8 0.4-20.4 10.8 1.1-43.8 9.2 0.6-34.6 
Table 3.2 Co-efficient of variation (%) for venous area, velocity and blood flow. 
 
Co-efficient of Repeatability in Young Subjects 
 Individual COR Overall COR Mean  Effect Size Median Range 
Venous area 0.003 0.0003-0.017 0.005 0.033 
Velocity 4.25 1.11-17.53 6.12 21.90 
Flow 5.91 0.23-13.76 6.43 39.76 
Table 3.3 Co-efficient of repeatability (COR) for individuals as a group (Young). 
 
Co-efficient of Repeatability in Elderly Subjects 
 Individual COR Overall COR Mean Effect Size Median Range 
Venous area 0. 005 00.1-0.02 0.006 0.035 
Velocity 7.19 2.22-18.12 8.20 21.77 
Flow 9.16 0.37-38.83 10.53 46.93 
Table 3.4 Co-efficient of repeatability (COR) for individuals as a group (Elderly). 
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3.4 Discussion 
Several studies have reported reduced ocular blood flow and poor blood flow regulation in 
glaucomatous eyes7-14. There is also evidence that primary open angle glaucoma is linked to 
factors related to ocular blood flow regulation and a breakdown of autoregulation7. Our 
group has demonstrated a reduction in the magnitude of retinal arteriolar vascular reactivity 
in both untreated primary open angle glaucoma and progressive primary open angle 
glaucoma27. There are also studies that show diabetic retinopathy is preceded by sub-
clinical disturbances in the retinal vasculature. Hence, many studies have considered the 
quantification of inner retinal blood flow as a promising investigation approach for the 
early detection and improved monitoring of various diseases. However, the results of inner 
retinal blood flow disturbance in DR have been contradictory28-37, although virtually all 
indicate some aspect of disturbance. 
This study shows that the Doppler FD-OCT can reliably and consistently measure retinal 
blood flow in healthy participants, despite the subjectivity of the vessel area determination. 
The Doppler FD-OCT offers a quantifiable and repeatable method of assessing retinal 
blood flow. Blue field entoptic and fluorescein angiographic techniques deliver mostly 
subjective or semi-quantitative measurements of retinal blood flow. Laser Doppler 
flowmetry offers flow values only in arbitrary units and readings between subjects are 
dependent on interpretation. Pulsatile ocular blood flow assessments are dependent on 
controversial assumptions of ocular physiology and measure total ocular blood flow, a 
majority of which arises from the choroidal circulation. 
Wang and co-workers used a single-beam FD-OCT to measure the total retinal blood flow 
of all vessels around the optic nerve head. Their results showed values of 45.6 ± 3.8μl/min 
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for TRBF with the co-efficient of variation of 10.5%23. Our results showed a range of 
variability in individual blood flow with a COV ranging from 0.4% in young subjects 
(median 7.5%) to 34.6% in elderly subjects (median 9.2%). Our data is in agreement with 
Wang and co-workers data23. There are several sources that might contribute to the 
individual variability including the impact of eye motion, tear film quality or normal 
biological variations. The individual variability may also reflect the quality of measurement 
and possibly the analysis method.  Subjects with higher COV values could be excluded 
from study based upon their outlier status.  
The differences in COV between the two groups (median 7.5% young group versus 9.2% 
elderly group) are negligible and the differences in COR between groups are relatively 
small (median 5.91μl/min, relative to a mean effect of 39.76μl/min for the young group 
versus median 9.16μl/min, relative to a mean effect of 46.39μl/min for the elderly group). 
This represents a difference in RBF calculations between sessions/days of approximately 
4μl/min in real terms or in terms of the known range of TRBF values a difference of 
approximately 8%.  
The co-efficient of variation relates the group mean SD of a given parameter as a function 
of the group mean effect (on a percentage scale). Therefore, comparison of the COV for 
young and elderly participants between venous area and venous velocity can be used to 
determine which of the two parameters contributes the greatest variability to the RBF 
value. We found that the COV for venous area to be approximately half that of the COV 
for venous velocity (i.e. 4.7 to 4.8% for area versus 10.4 to 10.8% for velocity). We 
conclude that the velocity measurement is the greater contributor to blood flow variability, 
a finding that is in agreement with that of the established CLBF methodology 38,39. A 
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mathematical perspective of this issue would be to argue that a summary velocity value is 
derived by dividing the measured area by the measured flow value. Consequently, the 
fundamental error components are Doppler angle error caused by motion error, vessel 
boundary segmentation error, Doppler phase error due to phase wrapping, residual bulk 
motion error (after compensation) and system phase noise (Huang D. Personal 
Communication). 
One of the advantages of OCT is the exceptional level of resolution used to discern the 
retinal vasculature. Another more established method to assess RBF is Laser Doppler 
velocimetry (LDV), which has been applied to investigate retinal blood velocities in the 
major arterioles and venules of the retina40. The most established instrument to utilize the 
LDV methodology is the Canon Laser Blood Flowmeter (CLBF), which simultaneously 
measures vessel diameter along with centerline blood velocity in order to derive blood flow 
values in absolute units41.  
Using the CLBF, the individual COVs for flow were reported to be from 4.8 to 37.3% 
(median 19.3%). The group mean CORs for flow were found to be 2.6μl/min (relative to a 
mean effect of 8.8μl/min). These data are from CLBF measurements of blood flow within 
retinal arterioles in normal subjects38. Our group studied the retinal arteriolar and venular 
blood flow in healthy subjects and concluded that the level of variability between the two 
visits was equivalent pre- and during hyperoxic provocation of vascular reactivity. This 
study showed the COV for venular flow was 9.9% during the baseline period39. These 
findings can be found in the Table 3.5. 
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Co-efficient of Variation (%) 
 
CLBF Diameter or 
FD-OCT Doppler 
Area 
Velocity Flow 
 Median Range Median Range Median Range 
CLBF 39 2.0 0.5-6.5 19.9 4.8-39.7 19.3 4.8-37.3 
CLBF/Arteriole 40 1.8 0.6-3.3 10.7 0.8-22.1 11.8 1.0-23.2 
CLBF/Venule 40 1.4 0.1-7.1 9.8 1.2-20.8 9.96 1.6-20.8 
FD-OCT Doppler 
/Young  4.7 0.8-16.8 10.4 0.1-28.9 7.5 0.4-20.4 
FD-OCT Doppler 
/Elderly 4.8 0.4-20.4 10.8 1.1-43.8 9.2 0.6-34.6 
Table 3.5 Comparison of Co-efficient of Variation (COV) using different Doppler based technologies. 
 
Doppler FD-OCT repeatability for young and elderly subjects, in terms of the COR, was 
found to be 6.43μl/min and 10.53μl/min, respectively; the acceptable level of between-
session variability needs to be interpreted based upon the magnitude of the effect size. The 
difference in repeatability between sessions was also greater in subjects with crowded 
vascular beds, which resulted in difficulty distinguishing the arteriolar from the venular 
Doppler phase shift signals (Figure 3.8). Other factors such as tortuous vessels or curved 
and tapering vessels can also play a role in the variability through the generation of 
irregular, or non-Poiseuille flow conditions. The within-session variability of blood flow 
measurements could be a result of eye motion, tear film or the anatomy of the vessels or 
intrinsic variation of RBF. The tear break up can alter the laser intensity projected onto the 
retina and may result in displacement of the laser from the center of the vessel due to 
optical blurring effects. We attempted to keep all parameters such as diet in both sessions 
the same. Other factors such as consuming red meat or caffeine could play a role in the 
difference as well42,43. These factors can contribute to the individual blood flow variation 
measured by Doppler FD-OCT. Another limitation of this study is that the maximum 
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detectable volume of the Doppler FD-OCT system is slower than the maximum flow 
velocity especially in retinal arterioles assuming equal flow in arteriole and venule; as a 
result, all reported values were based upon venular measurements only.  
 
Figure 3.8 Fundus image of an elderly subject with tortuous vessels and high COR value. 
Factors that will cause Doppler FD-OCT measurements to be invalid fall into three main 
causes: Objects that are close to perpendicular to the incident OCT beam will result in a 
relatively weak Doppler signal because the Cosine of 90° is zero. Also, errors in the 
measurement of vessel lumen area will greatly influence the estimation of flow and this 
effect is compounded by the fact that the area estimation requires the subjective 
determination of the Doppler signal boundary and then the subjective assignment of 
confidence in the area estimation. In addition, the impact of eye movements will introduce 
further error into the estimation of vessel lumen area. 
To summarize, the degree of variability and repeatability can differ significantly between 
individuals but overall Doppler FD-OCT gave consistent and repeatable blood flow 
measurements within retinal venules in normal subjects.  
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4.1 Introduction 
The retina is a tissue with extraordinary metabolic demand, especially for key molecules 
such as oxygen, glucose and amino acids 1,2. This makes the retina more susceptible to 
hypoxia. Retinal blood flow disturbance in the early stages of diabetes along with hypoxia 
is thought to play a role in pathological retinopathy. Retinal oxygen consumption has been 
thought to decrease in diabetes, which might be due to reduction in metabolism of neurons, 
or to cell death. In other words, diabetic retinopathy (DR) is a microvascular and 
neurodegenerative disorder characterised by damage to the retinal capillaries and retinal 
glial, Müller and associated neuronal cells 3-6.  DR results in disturbed delivery of oxygen to 
retinal cells, which in turn will cause hypoxia in retinal tissue. A relationship between the 
pathogenesis of DR and retinal hypoxia has been found. Hypoxia is thought to provoke 
neovascularization and retinal edema 7. Therefore, it is critical to study the regulation of 
oxygen supply to the retina in order to learn more about the pathophysiology of DR and 
diabetes.  
Studies have shown a reduction in retinal oxygen consumption in diabetes-induced rabbits 8 
and cats 9, although there are conflicting results about arterio-venous oxygen differences 
and consumption in the retina of diabetic rats 10-12. However, the arterio-venous difference 
has been shown to decrease in all the stages of retinopathy13.  
One study indicated a reduction in retinal venular blood oxygen saturation during 
hyperglycemia in diabetic patients without retinopathy and also found a correlation 
between the amount of venous oxygen saturation reduction and the duration of diabetes 14. 
Holekamp and co-workers (2006) found lower partial pressure of oxygen in the vitreous of 
a patient with proliferative diabetic retinopathy than in the vitreous of non-diabetic patients 
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immediately prior to vitrectomy 15. Likewise, another group found a lower partial pressure 
of oxygen in the mid-vitreous in diabetic patients when compared to non-diabetic patients 
16 and also reported higher partial pressures of oxygen at the posterior pole in patients with 
proliferative diabetic retinopathy compared to non-diabetic patients undergoing vitrectomy 
17. Others have found retinal oxygen saturation in arterioles and venules to be higher in 
diabetic patients 18. A trend of increasing arterial and venous oxygen saturation correlating 
to the severity of retinopathy in diabetic patients has been reported, though the arterial 
increase is not significant 13. The same group showed that flicker light stimulation leads to a 
rise in both central retinal arterial and venous diameter while only resulting was a rise in 
venous, and not in arterial, oxygen saturation. They presented a reduced flicker response 
for NPDR patients compared to controls 19. Another study indicated a trend for higher 
retinal oxygen saturation in NPDR group but this was insignificant when compared to 
controls, while significance was only observed when comparing controls to severe-NPDR, 
PDR 20. 
Tiedeman and co-workers 14 used a dual wavelength retinal imaging system in diabetic 
subjects without clinical evidence of diabetic retinopathy during normoglycaemia and 
hyperglycaemia. They reported evidence of significantly higher retinal oxygen 
consumption during hyperglycemia. Hammer and co-workers showed higher venular 
oxygen saturation with the severity of DR in subjects with mild non-proliferative DR and 
in subjects with proliferative DR but the difference in mild-to-moderate NPDR didn’t reach 
significance 21. An insignificant increase in retinal oxygen saturation was also reported 
comparing healthy controls to non-proliferative diabetic retinopathy subjects, though 
significance was only reported for severe-non-proliferative NPDR and proliferative DR21. 
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This suggests that imaging techniques such as hyperspectral retinal imaging may provide 
improved methods of predicting the probability of onset, differentiating the severity and of 
observing progression of diabetic retinopathy in vivo. A recent study by Man and co-
workers 22 suggested that eyes with longer axial length show lower retinal function and 
hence lower O2 consumption; therefore eyes with longer axial length are fairly less hypoxic 
when diabetes exists, which may partly explain the reduced risk of DR in these eyes. 
Hardarson and co-workers also reported increased retinal blood oxygen saturation in 
patients with DR 23.  
In terms of retinal oxygen saturation imaging, the technology provided by Optina Inc 
(formally known as Photon etc) permits the acquisition of hyperspectral retinal images at 
background light levels (Bragg tunable filter; BTF) far lower than any of the competing 
technologies, thereby avoiding flashing induced disturbance of retinal metabolic status. 
Oxygen saturation in diabetic patients could offer valuable information for better 
understanding of changes in metabolism in DR.  
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4.2 Methods 
4.2.1 Sample 
This study received approval by the University of Waterloo Office of Research Ethics and 
the Research Ethics Board of the University Health Network, University of Toronto, 
Canada. Informed consent was obtained from each subject after explanation of the nature 
and possible consequences of the study according to the tenets of the Declaration of 
Helsinki. The sample consisted of 31 volunteers in two groups of subjects with mild-
moderate NPDR (n=14; mean age 66.3; SD 9.1 years) and aged matched healthy controls 
(n=17; mean age 69.70; SD 6.26 years) (Table 4.1). One eye of each subject was selected 
for the study. All subjects had a corrected visual acuity of 20/40 or better. Subjects were 
excluded for a family history of any other ocular disease, apart from diabetic retinopathy. 
None of the patients with NPDR had received treatment of any kind for their retinopathic 
changes or had any evidence of diabetic macular edema or any other sight-threatening 
characteristic. Subjects abstained from caffeine for at least 12 hours before the study.  
Group Group Mean Age (SD) Male to Female Ratio 
Group Mean A1c 
(SD) 
Control 69.1 (5.7) 8 M : 9 F 5.5 (0.4)* 
NPDR 66.3 (9.1) 5 M : 9 F 7.5 (1.5) 
Table 4.1 Group mean age, male to female ratio and A1c (A1c: glycosylated hemoglobin. M; male, F; 
Female. NPDR; Non-proliferative diabetic retinopathy) *(difference between control and NPDR group 
p<0.001) 
4.2.2 Assessment of Retinal Blood Oxygen Saturation  
A prototype custom-built fundus camera (H-8.5 HR Camera, Optina, QC, Canada) is the 
foundation of the hyperspectral imaging system that incorporates a tunable laser source 
(TLS) as the light source. The TLS makes it possible to change wavelengths within a 
spectral range of 400-1000nm (visible to IR) and with a half peak bandwidth of 2nm. The 
	   65	  
TLS is built on Photon etc’s Bragg grating filtering technology which permits rapid 
wavelength presentation from the steady and powerful super-continuum light source 
(Leukos-SM-30-OEM, Leukos Innovative Optical Systems, Limoges, France). The TLS 
can be electronically tuned with an operating ambient temperature of 10-30°C. An 
automatic spectral system is incorporated into the system to achieve exact and accurate 
(<1nm) wavelength choice. The sensitive 1.3MPixel (1392 x 1040 pixel) 14-bit CCD 
camera (Pixelfly USB, PCO AG, Kelheim, Germany) used in this system is for high 
definition imaging.  The imaging system is operated by using PhySpec (Photon Etc, 
Montreal, QC, Canada), a programme that manipulates the Bragg tunable filter (BTF) and 
CCD camera to allow aspects such as operator defined wavelength range and wavelength 
interval. A low power white light source (delivering about 100mW over 420nm to 2400nm) 
and the Bragg tuneable filter are used to exclude the use of conventional flash lamp, and 
therefore all images are acquired at low light levels, thereby minimizing any potential 
change of the metabolites and photopigment status in the eye. A diagonal field of view of 
approximately 37.4° is sustained by the opto-mechanics of the system 24. 
After pupil dilation with one drop of Tropicamide 1% (Alcon, Mississauga, Canada) each 
subject had six repeated sets of retinal images captured at 586 and 605nm using the HRC. 
Optical densities were extracted for first-degree arterioles and venules manually and the 
repeatability of retinal reflectance was compared sequentially. PHySpec (Photon etc.), a 
custom-designed software, is used to acquire hyperspectral images and to extract reflected 
light intensity of the retinal vessels. The final spectral cubes were normalized and 
registered independently after spectral image acquisition. 
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The normalized spectral cubes underwent a registration procedure to correct for 
wavelength-dependent optical deformations (scaling) and fine eye movement (translation). 
The scaling correction is continual in time and is determined during the instrument set-up 
and qualification (Photon etc.). PHySpec comprises a registration procedure permitting 
translation correction between images in the cube. Details of the PHySpecTM software have 
been published elsewhere 24.  
ImageJTM software was used to provide reflectance profiles across a retinal vessel at a 
predetermined site; then ODR was calculated using the Minimum-Maximum methodology. 
In the suggested Minimum-Maximum Method, optical density (OD) of a retinal vessel is 
derived from the log ratio of minimum and maximum intensity values along a line drawn 
perpendicular to the long axis of the retinal vessel. 
 
Retinal blood oxygen saturation was measured within one disc diameter from optic nerve 
head in first degree arterioles and venules. The analysis was performed by equating the 
reflected light intensity within a vessel to the light intensity of the adjacent retina at 
isosbestic (oxygen insensitive) and non-isosbestic wavelengths.  
The light intensity from the retinal area adjacent to the vessel is used to determine the 
maximum reflected intensity (i.e. a measurement site assumed to be unaffected by 
hemoglobin absorption) and the center of the vessel (i.e. assumed to be maximally 
impacted by hemoglobin absorption) is used to determine the minimum reflected intensity. 
These measurements are used to calculate the OD ratio (ODR) value (=OD605/OD586), which 
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represents the OD value of oxygen sensitive wavelength as a function of the OD value 
oxygen insensitive wavelength 25. 
The ODR and SO2 values were calculated for both retinal arterioles and venules. The 
arteriovenous differences were in the blood oxygen saturation between the arterial blood 
and the venous blood. 
The measurements were taken at 6 different wavelengths (hemoglobin wavelength 
insensitive at: 548nm, 569nm, 586nm and hemoglobin wavelength sensitive at 600nm, 
605nm, 610nm). The most consistent results in terms of retinal blood SO2 repeatability 
were achieved by the wavelength combination OD605/OD586, 586nm as insensitive to 
differences in blood oxygenation and gives better results compared to other hemoglobin 
insensitive wavelength because of the proximity to the hemoglobin sensitive wavelengths. 
The 605nm wavelength also provided improved repeatability of results.  
4.2.3 Statistical Analysis 
Two-tailed t-test was performed to determine the significance of any change. The 
difference in retinal oxygen saturation was considered significant when the p-value was 
less than or equal to 0.05.   
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4.3 Results 
In diabetic patients, the mean retinal venular blood oxygen saturation (SO2) was higher 
than in the healthy controls (94.65±2.2% vs 92.97±1.6%, p=0.0151, Figure 4.1).   
Similarly, the mean retinal arteriolar blood SO2 was higher in diabetic patients than in 
controls (64.13±4.3% vs 55.90±4.8%, p<0.001, Figure 4.2), while the mean arteriovenous 
SO2 difference was lower for the diabetic patient group (30.57±4.76 vs. 37.05±4.95, 
p=0.001). 
Both arteriolar and venular SO2 values were significantly different between the groups.  
The difference between the groups in SO2 of the venules was higher than the difference in 
the arteriolar SO2 between the two groups. This resulted in a significant difference in 
arteriovenous difference between two groups.  
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Figure 4.1 Oxygen saturation in first-degree arteriole. The box plots illustrate retinal arteriolar blood oxygen 
saturation in control and NPDR participants. The error bars show the non-outlier range. 
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Figure 4.2 Oxygen saturation in first-degree venules. The box plots illustrate retinal venular blood oxygen 
saturation in control and NPDR participants. The error bars show the non-outlier range.   
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4.4 Discussion 
The results of this study demonstrate a higher retinal SO2 in the major retinal arterioles and 
venules in patients with untreated, non sight-threatening, mild-to-moderate NPDR than 
when compared to healthy controls. This difference was much more evident in venules 
rather than arterioles. Hardarson and co-workers data is in strong agreement with the 
results of our study, since they also showed higher retinal SO2 values in diabetic patients18. 
Using different technology and a smaller sample, Hammer and co-workers found a trend 
for an increase of retinal SO2 for both arterioles and venules but they could not show a 
significant difference between controls and patients with mild-moderate NPDR 21. 
Khoobehi and co-workers showed that retinal SO2 increased in diabetic patients but these 
changes were only significant in severe NPDR and PDR groups when compared to 
controls20. Using correlation analysis Khoobehi and co-workers showed that the severity of 
DR had an impact on the increase of SO2 in diabetic patients 20. There was a drawback in 
the study of Khoobehi and co-workers because their groups were not age-matched. In my 
study, patients with relatively mild-to-moderate NPDR which did not yet require treatment 
were shown to have higher retinal arteriolar and venular SO2 values when compared to 
controls.  
This study showed that the SO2 values in the major retinal vessels were greater in patients 
with mild-to-moderate NPDR than in controls. The higher retinal venule SO2 may be 
explained by lower oxygen release to, or lower consumption by, the retinal tissues 
secondary to retinal cell death. However, SO2 values alone are difficult to interpret since: 
Retinal O2 Delivery = [1.39 x Hb x SaO2 + (0.003 x PaO2)] x blood flow 
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Theoretically, each gram of Hemoglobin binds 1.39 ml of oxygen. The oxygen saturation 
curve represents a PaO2 (arterial oxygen tension) as a function of SaO2 (Arterial SO2). The 
haemoglobin concentration is calculated by production, destruction and loss. 0.003 stands 
for the oxygen solubility coefficient in human plasma 
The implications of the factors in the equation above are that if retinal O2 metabolism 
increases in NPDR then the results may be explained either by an increase in SO2 or an 
increase in blood flow or an increase in both SO2 and retinal blood flow. This emphasizes 
the need to measure retinal blood flow and retinal SO2, ideally simultaneously.  
 As mentioned in other papers 21, the higher retinal SO2 in NPDR might be a result of 
capillary occlusion and permanent closure of blood vessels in conjunction with other vessel 
changes in NPDR 3. This will result in decreased capillary density in some areas and, 
consequently, hypoxia.  However, whether or not retinal SO2 derives the development of 
DR, or simply changes subsequently, is undetermined. Prospective studies need to be 
undertaken which assess the change in oxygen metabolism and retinopathy development 
over time to determine which parameter is disturbed first.  
An elevated SO2 in retinal arterioles has been suggested to reflect the magnitude of 
glycated hemoglobin (A1c). However, in this study, no relationship was found between 
arteriolar SO2 and A1c. Similarly, Gilmore and co-workers 26,27 reported no correlation 
between change in hemodynamic flow parameters and blood glucose, A1c and duration of 
diabetes. This finding was in agreement with other studies which did not find correlation 
between blood flow and blood glucose 28. However, Pemp and co-workers 29 reported 
decreased retinal blood flow with decreasing plasma glucose using the glucose clamp 
technique in subjects with type 1 diabetes with no or mild DR. Other studies have also 
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shown higher blood flow with increased blood glucose 30,31. Protein glycation and 
production of advanced glycation end products (AGEs) may contribute to reduction of the 
rate of oxygen diffusion out of the arterioles and hence a higher magnitude of retinal blood 
SO2 32.  
The mean arterio-venous difference was 36.89±7.02 for healthy subjects and 30.78±4.76 in 
NPDR subjects (p=0.009). The lower arterio-venous difference in the NPDR group could 
be the result of less oxygen demand that especially impacts the venules in NPDR. 
Hardarson and co-workers reported the arteriovenous difference as insignificant. This could 
be explained by the fact that their population was not age-matched 23.  
Retinal vessel blood oxygen saturation was higher in NPDR when compared to control 
participants. This could be as a result of reduced oxygen utilization, probably as a result of 
neuronal cell atrophy, in the diabetic group with mild-to-moderate NPDR. 
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5.1 Introduction 
Diabetic retinopathy (DR) is a primary source of visual loss in the world, including North 
America1. DR appears to be allied closely to disturbances in the vasculature. Hence, many 
studies have considered the inner retinal blood flow. However, the results of inner retinal 
blood flow disturbance in DR have been generally contradictory2-11, although many studies 
indicate some aspect of disturbance. The study of metabolic disturbance as a functional 
diagnosis is a potentially encouraging biomarker for the detection of early reversible 
pathological changes before they become clinically evident.  
Elevated retinal blood flow has been classically proposed to ultimately cause the progress 
of DR, probably because of amplified frictional forces (i.e., shear stress) on the endothelial 
cells lining the walls of retinal vessels12. However, the exact nature of the blood flow 
disruption is debatable, perhaps due to the variety of methods used to measure retinal 
hemodynamics, the diverse stages of retinopathy considered, and the diversity of the 
diabetic groups13. From a clinical perspective, the assessment of ocular hemodynamics 
proposes an earlier detection of DR and improved DR severity differentiation and perhaps a 
flag for new treatment opportunities. Retinal hypoxia is thought to promote the production 
of VEGF and the development of macular edema and neovascularization. Measurement of 
retinal oxygenation in patients with diabetes may help to assess the severity of DR and the 
response to novel “prophylactic” treatments. Ultimately, knowing the blood flow to, and 
the oxygenation of, the retinal tissue will permit the assessment a metabolic parameter of 
the retinal tissue, namely oxygen utilization (also termed “retinal oxygen delivery”). 
It has been suggested that change in blood circulation leads to functional damage and broad 
retinal tissue impairment and disturbance during diseases such as DR 14. In this respect, it 
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will be critical to study the oxygen distribution or consumption of the retina and it’s 
alteration in response to DR since RBF or SO2 alone represent only part of the required 
information to calculate retinal oxygen utilization. Measurement of these alterations could 
be used to improve the early detection and management of diseases such as diabetes / 
diabetic retinopathy. Most of the non-invasive optical techniques that are used to measure 
the retinal oxygen saturation (SO2) rely on measuring differences between hemoglobin and 
oxygenated hemoglobin (Hb and HbO2) light absorption (see Section procedures for 
complete methodology explanation). Simultaneous retinal blood flow measurement and 
retinal hemoglobin oxygenation are required to assess absolute values of oxygen delivered 
to the retina 15,16. The non-invasive quantification of oxygenation of the retina will be 
feasible by retinal oximetry, which in turn may offer a sensitive and predictive biomarker. 
Quantification of blood flow and oxygenation of the retina will permit the assessment of 
the tissue oxygen utilization. 
Assessing oxygen concentration in the retina has been achieved using O2-sensitive 
microelectrodes introduced into the eye 17-20. While this technique is precise and can 
accurately define oxygen saturation, the invasive nature of the technique limits its’ usage to 
animal models and disqualifies it from clinical purpose. Alternative methods using the 
introduction of a phosphorescent dye has been utilized to derive oxygen concentration in 
the optic nerve head and retinal vessels19,21. Nonetheless, the use of such a dye in humans is 
not accepted due to toxicity concerns. Imaging techniques established on oxygenated 
hemoglobin and reduced hemoglobin (i.e. deoxyhemoglobin) and their spectral changes 
have been used in humans to non-invasively assess oxygen saturation in retinal vessels 18,22-
26. Hickam and co-workers first proposed a non-invasive measurement of the oxygen 
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saturation using a two-wavelength (510, 640nm) photographic-based method. Following 
that, another two-wavelength (470, 515 nm) technique was developed to measure oxygen 
saturation. These techniques, however, were laborious. Later, Pittman and Duling 16 
introduced a three-wavelength spectrophotometer method for oximetry. Delori 14 
introduced the first scanning retinal oximeter illuminating with multiple wavelengths. 
Another group 25 used a grating spectrograph to acquire spectra and applied a multi-
wavelength curve fitting technique for saturation estimation. Oxygen saturation in retinal 
vessels has been found to be greater in diabetic retinopathy in contrast to control subjects 27.  
Assessment of oxygenation in the retina may facilitate the early detection of diabetic 
retinopathy. The aim of this study was to investigate the relationship between retinal blood 
flow and retinal blood oxygen saturation in NPDR. 
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5.2 Methods 
5.2.1 Sample 
This study received approval by the University of Waterloo Office of Research Ethics and 
the Research Ethics Board of the University Health Network, University of Toronto, 
Canada. Informed consent was obtained from each subject after explanation of the nature 
and possible consequences of the study according to the tenets of the Declaration of 
Helsinki. The sample consisted of 28 volunteers in two groups of subjects with mild-to-
moderate NPDR (n=13; mean age 67.3; SD 10.2years; Table 5.1) and aged matched 
healthy controls (n=15; mean age 68.1±years; SD 6.0 years; Table 5.1). One eye of each 
subject was selected for the study. All subjects had a corrected visual acuity of 20/40 or 
better. Subjects were excluded for family history of any other ocular disease, apart from 
DR. None of the patients with NPDR had received treatment of any kind for their 
retinopathic changes or had any evidence of diabetic macular edema or any other sight-
threatening characteristic. Subjects abstained from consuming caffeine 12 hours before the 
study. 
Group Group Mean Age (SD) Male to Female Ratio 
Group Mean A1c 
(SD) 
Control 68.1 (6.0) 5 M : 10 F 5.4 (0.3) 
NPDR 67.3 (10.2) 5 M : 8 F 7.5 (1.6)* 
Table 5.1 Group mean age, male to female ratio and A1c (A1c: glycosylated hemoglobin. M; male, F; 
Female. NPDR; Non-proliferative diabetic retinopathy). *(difference between control and NPDR group 
p<0.001) 
5.2.2 Assessment of Retinal Blood Flow  
Doppler Fourier-domain optical coherence tomography (Doppler FD-OCT) is used to 
measure retinal blood flow. This novel imaging method offers retinal blood flow 
assessment using a physical phenomenon called Doppler phase shift 28. The principle of the 
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Doppler phase shift has been incorporated into the commercially available Doppler FD-
OCT (Optovue Inc, Freemont, CA). Doppler FD-OCT produces high resolution cross 
sectional images of the retina. This instrument uses a laser light source of 841nm with 
bandwidth of 49nm with an incident power of 500μW on the cornea. These factors deliver 
an axial resolution of 5.4μm in tissue 29. System transverse resolution was 20μm 30. 
Contradictory to morphological FD-OCT systems that generates just structural images, the 
prototype Doppler FD-OCT evaluates the Doppler phase shift between two consecutive A-
scans. Light reflected from moving particles undergoes Doppler phase shift.  
Flow velocity is determined by: 
 
v = ΔΦ. λ!4π.T.n. Sin(θ) 
 
Where v is the flow velocity in an OCT voxel, and ΔΦ=Φ1-Φ2 is the Doppler phase shift. 
Φ1 and Φ2 are the phase of voxels in the same position in consecutive OCT axial scans, λ0 
is the source center wavelength, n is the refractive index of the medium, T is the time 
interval between consecutive scans and θ is the Doppler angle defined by the OCT beam 
axis relative to the line perpendicular to blood vessel flow axis 31. 
5.2.3 Assessment of Retinal Blood Oxygen Saturation  
The principal of the oximeter has been described elsewhere 32 but briefly a prototype 
custom-built fundus camera (H-8.5 HR Camera, Optina, QC, Canada) is the foundation of 
the hyperspectral imaging system that incorporates a tunable laser source (TLS) as the light 
source. The TLS, built on Photon etc’s Bragg grating filtering technology, makes it 
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possible to transfer wavelengths with a half peak bandwidth of 2nm (ranged from 400nm to 
1000nm). The TLS permits rapid wavelength presentation from the steady and powerful 
super-continuum light source (Leukos-SM-30-OEM, Leukos Innovative Optical Systems, 
Limoges, France). The imaging system is administered by using PhySpec (Photon Etc, 
Montreal, QC, Canada), a software programme that operates the Bragg tunable filter (BTF) 
and CCD camera to permit factors such as operator defined wavelength range and 
wavelength interval. A low power white light source (delivering about 100mW over 420nm 
to 2400nm) and the Bragg Tuneable Filter are utilized to eliminate the use of conventional 
flash lamp, and consequently all images are obtained at low light levels, thus decreasing 
any potential change of the ocular metabolites and photopigment status 32.  
5.2.4 Procedures 
Refraction, logMAR visual acuity, Goldmann applanation tonometry and resting blood 
pressure were assessed prior to dilation of the study eye. The pupil of the study eye was 
dilated using Tropicamide 1% (Alcon, Mississauga, Canada) at the beginning of each visit 
to achieve an adequate view of the fundus for the retinal blood flow image acquisition and 
retinal blood oxygen saturation measurements. A minimum of six separate FD-OCT 
Doppler measurements (i.e. each separate measurement comprising an upper nasal pupil 
scan and a lower nasal pupil scan) and six blood oxygen saturation measurements were 
acquired.  
5.2.5 Analysis  
A Pearson correlation analyses and linear regression were performed to examine the 
relationship between retinal blood flow and retinal blood oxygen saturation. 
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5.3 Results 
The results of this study showed that the retinal blood flow was significantly lower in 
diabetic patients (before removing extreme or outlier points, 42.66 vs 32.97 μl/min; 
p=0.004 and after removing the extreme and outlier points 42.08 vs 33.86 μl/min; p=0.005, 
Figure 5.1) 
 
 
Figure 5.1 Box plots representing venous retinal blood flow in control and NPDR patients (42.66 vs 32.97 
μl/min; p=0.004). Box plots illustrating group mean retinal blood flow. The * represents extremes and the 
small circles represent outliers. The error bars show the non-outlier range.  
 
 Control NPDR T-test (p-value) 
SO2 (Venule) 56.29±4.7 62.55±5.7 p=0.003 
Total RBF 42.66±7.55 32.97±9.2 p=0.004 
Table 5.2 Group mean values for blood oxygen saturation and total retinal blood flow (RBF) for non-
proliferative diabetic retinopathy (NPDR) and aged-matched controls.  
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Figure 5.2 shows retinal venous blood flow as a function of retinal blood oxygen saturation 
in controls and Figure 5.3 illustrates retinal venous blood flow as a function of retinal blood 
oxygen saturation in NPDR group. The result did not show any relationship between retinal 
blood flow and oxygen saturation in either of the groups.  
 
 
 
Figure 5.2 Oxygen saturation as a function of retinal venous blood flow in controls (r=0.243, p=0.34)  
 
 
 
 
y = -0.15x + 62.682 
R2 = 0.05906 
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Figure 5.3 Oxygen saturation as a function of retinal venous blood flow in NPDR group (r=0.228, p=0.45) 
 
 
 
 
  
y = 0.1362x + 57.983 
R2 = 0.0522 
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5.4 Discussion 
It has been shown that the DR is associated with early retinal vascular dysregulation. 
Therefore, many studies have investigated the inner retinal blood flow. Nevertheless, the 
results of inner retinal blood flow disturbance in DR have been contradictory 2-11, although 
virtually most indicate some aspect of disturbance. It has been reported that NPDR patients 
or patients without retinopathy have fluctuated retinal blood flow at different times of the 
day due to fluctuation in their plasma glucose which was suggested as a possible cause of 
microvascular changes in DR 33. Our results showed lower retinal blood flow in NPDR 
when compared to controls (p=0.004). There was no correlation between total retinal blood 
flow and retinal venular blood oxygen saturation. This might be as a result of small sample 
size.  
The direction of the change in total retinal blood flow in DR is controversial 5,34-36. The 
present study showed a reduction in retinal blood flow and increased in retinal blood 
oxygen saturation when comparing NPDR subjects with controls. Our oximetry data is in 
agreement with Hardarson’s results 37. Hardarson interpreted this result to occur due to 
impaired diffusion of oxygen to the adjacent tissue through the thickened arteriolar walls of 
diabetic subjects. Higher blood flow would be inclined to reduce the release of oxygen 
from haemoglobin and therefore would result in reduced diffusion of oxygen across the 
arteriolar walls 37.  
The blood flow in NPDR group is lower when compared to controls. This might be 
explained by the concept of mobile oxygen sensor introduced by Ellsworth and co-workers 
38. This idea is based on the fact that hemoglobin in red blood cells (RBC) becomes 
deoxygenated and consequently a changes form which transmits to the RBC membrane and 
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results in the release of ATP. The released ATP binds to the endothelial cell purinergic 
receptor and leads to arteriolar smooth muscle cell relaxation, higher blood flow and more 
oxygen delivery 39. High SO2 represents a greater magnitude of oxyhemoglobin to 
deoxyhemoglobin in the vessels, which would result in less binding between ATP and the 
receptors on the endothelial cells. Therefore there might be decreased blood flow and lower 
oxygen delivery to the tissue. 
In summary, the data from this study suggest that there was no association between retinal 
blood flow and retinal blood oxygen saturation. Given that there is no correlation between 
SO2 and RBF, the results of this pilot work suggest that there is a need to measure both SO2 
and RBF in order to calculate retinal oxygen utilization. 
The combination of retinal oxygen saturation and retinal blood flow can be used to extract 
more information about retinal metabolism since:  
Retinal O2 Delivery = [1.39 x Hb x SaO2 + (0.003 x PaO2)] x blood fow 
Theoretically, each gram of Hemoglobin binds 1.39 ml of oxygen. The oxygen saturation 
curve represents a PaO2 (arterial oxygen tension) as a function of SaO2 (Arterial SO2). The 
haemoglobin concentration is calculated by production, destruction and loss. 0.003 stands 
for the oxygen solubility coefficient in human plasma. 
The retinal oxygen saturation without simultaneous retinal blood flow measurement 
represents the circulation delivery for the cell 40. There are some methods that 
simultaneously measure retinal blood SO2 and retinal blood flow measurements, which are 
restricted to animals.  
 
	   86	  
6  Multiplex Analysis of Inflammatory and Angiogenic Biomarkers in 
Aqueous Humor in Mild-to-Moderate Non-Proliferative Diabetic 
Retinopathy 
 
Faryan Tayyari, Lee-Anne Khuu, Jeremy Sivak, Michael Brent, Shaun Singer, John G 
Flanagan, Christopher Hudson 
 
 Design Recruitment 
Acquisition 
Of Data 
Analysis 
Writing / 
Publication 
F. Tayyari x x x x x 
L. Khuu x x x x  
J. Sivak x   x  
M. Brent  x x   
S. Singer  x x   
J. Flanagan x     
C. Hudson x   x x 
Table detailing role of each author in this publication (x denotes significant contribution)  
	   87	  
6.1 Introduction 
Diabetes triggers a number of retinal metabolic and physiologic abnormalities that can 
contribute to diabetic retinopathy (DR). Many of these retinal abnormalities in diabetes are 
consistent with inflammation. DR is illustrated by damage to the retinal microvascular 
causing vascular leakage and ischemia-induced retinal neovascularization as a result of the 
classic pathways: the polyol pathway, protein kinase C (PKC) activation, increased 
advanced glycation end-product (AGE), and the superoxide pathway 1. Each of these 
pathways can promote expression of angiogenic biomarkers such as vascular endothelial 
growth factor (VEGF), Leptin, Angiopoietin 2 (Ang 2), Epidermal growth factor (EGF), 
Transforming growth factor beta (TGF-β), Heparin-binding EGF-like growth factor (HB-
EGF), Hepatocyte growth factor/scatter factor (HGF/SF), and Interleukin-8 (IL-8) 2,3. 
VEGF is a well-known persuasive angiogenic factor that stimulates retinal 
neovascularization, leading to tractional retinal detachment and vitreous hemorrhage, 
which are important because they represent the most severe causes of visual loss in patients 
with PDR 4,5. There is a wealth of evidence that during retinal and choroidal 
neovascularization and the formation of diabetic macular edema, hypoxia intensely 
stimulates VEGF expression by stabilization of HIF-1 (hypoxia-inducible factor-1) 
transcription 6-8. Previous studies also specify the important role of VEGF in the breakdown 
of the blood-retinal barrier in DR. Vascular hyper-permeability secondary to tight junction 
impairment between vascular endothelial cells and neovascularization are obvious of 
vascular endothelial cell dysfunction induced by diabetes. VEGF plays an important role to 
mediate these early and late vascular alterations 9-11.  VEGF has also been found markedly 
increased in DR and was significantly correlated with DR severity 5. Angiogenesis is 
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caused by disruption between the production of angiogenic activator such as VEGF and 
angiogenic inhibitors such as angiostatin and pigment epithelium-derived factor (PEDF) 
12,13. The amplified production of angiogenic activators and reduced production of 
angiogenic inhibitors caused by local hypoxia, disturbs the balance between the desirable 
and undesirable regulators of angiogenesis. Subsequently, over proliferation of capillary 
endothelial cells occurs which leads to neovascularisation 13. 
Ang 2 is one of the important growth factors of hypoxia-induced microvascular changes 
and is significantly involved in the initiation of retinal neovascularization. Angiopoietin 
molecules bind to the receptor tyrosine kinase, Tie2. The Angiopoietin molecules are 
growth factors that regulate the development of physiological angiogenesis and 
pathological neovascularization 14,15.  Another study revealed that vitreal Ang 2 increased in 
PDR and they have suggested a relationship of Ang 2 and VEGF with angiogenic activity 
in PDR 16. Another study proposed that Ang 2 is expressed by hypoxia and VEGF in 
bovine aortic endothelial cells 17. Others showed that Ang 2 is playing a role in pericyte 
recruitment and pre-retinal vessel formation under physiological and pathological disorders 
18. There is also evidence that Ang 2 is involved in pericyte apoptosis by α3β1 integrin 
signaling in DR 19. Ang 2 has been shown to be elevated in the vitreous of patients with 
clinically significant macular edema (CSME) 20 suggesting a possible role in the alteration 
of the blood-retinal barrier. Another study suggested that increased Ang 2 changes result in 
dysfunction of VE-cadherin causing in greater vascular permeability. Consequently, Ang 2 
might be involved in elevated vaso-permeability in DR21.  
Leptin, an adipocyte-derived hormone, is an energy metabolism regulator and is associated 
with diabetes mellitus through its metabolic actions. Leptin stimulates endothelial 
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proliferation and angiogenesis 22. Results describing the association between serum leptin 
and diabetic micro-angiopathies are variable. Sari and co-workers 23 did not find any 
difference in the leptin levels in serum between patients with and without diabetic 
nephropathy, retinopathy and neuropathy. Furthermore, Asakawa and co-workers 24 
reported no relationship in the leptin level and micro-angiopathies in Japanese patients of 
type 2 diabetes. However, Freuhwald-Schultes and co-workers 25 reported high serum 
leptin amounts in type 2 diabetes patients with early stages of renal disease, (i.e., 
macroalbuminuric nephropathy and microalbuminuric), while serum leptin levels did not 
significantly show any association with diabetic neuropathy. Jung and co-workers 26 did not 
find any relationship between leptin concentrations and diabetic retinopathy.  
Complicated events of interactions between retinal cells with growth factors and cytokines, 
extracellular matrix proteins and metallo-proteinases trigger the development of 
proliferative retinal diseases 27-29. HGF is one of these growth factors that has been studied. 
Its receptor is the c-met, a transmembrane tyrosine kinase 30.  An elevated HGF level in 
patients with type 1 diabetes mellitus with PDR and the relationship between progression 
of DR and the concentration of HGF was suggested as a role of HGF in the pathogenesis of 
PDR 31. 
HGF is an endothelium specific growth factor with more potent mitogenic activity than that 
of basic fibroblast growth factor (b-FGF), VEGF, interleukin 6 (IL-6), and interleukin 1 
(IL-1) 32,33. The HGF concentration in the vitreous of patients with PDR has been shown to 
be higher when compared to non-diabetic patients 34. In addition, it has been suggested that 
HGF might affect the progression of DR 35. 
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Inflammatory leukocyte recruitment constitutes one of the key pathological stages in DR. 
Diabetes has been shown to up-regulate several pro-inflammatory mediators in the retina, 
such as ICAM-1, and this localized inflammatory process is considered to be part of the 
development of DR 36-39. Retinal vascular ICAM-1 expression is elevated by VEGF. This 
may stimulate retinal leukostasis in diabetic eyes 40. Increased expression of ICAM-1 has 
been demonstrated to show an association with the severity of retinopathy 41. There is also a 
direct relationship between ICAM-1 and VEGF-induced vascular permeability 42, as well as 
evidence that pigment epithelium-derived factor (PEDF) decreases the hypoxia-induced 
ICAM-1 expression 43. Nowak and co-workers also reported high concentration of ICAM-1 
in DR 44. 
 Anomalous interactions between the endothelial cell and pericytes might be implicated in 
diabetic microangiopathy 45. There are some pathways of interaction between the 
endothelial cells and pericytes. One of these communication paths is TGF signaling, which 
is important for pericyte differentiation 46,47. Pericytes make the vasculature stable; 
modulate (rather than majorly control) blood flow at the local tissue level and control 
endothelial proliferation. One of the hallmarks of early changes in diabetic retinopathy is 
pericyte loss 48. Another structural hallmark is thickening of the capillary basement 
membrane. These changes along with others seen in diabetes such as increased blood 
viscosity might result in occlusive angiopathy and a consequent tissue hypoxia. Growth 
factors such as TGF-β and VEGF might be involved in basement membrane thickening 49.  
It has been proposed that increase of serum proteins due to microvascular disturbances and 
hypoxia might be a cause for vitreous alterations of Insulin-like growth factor I (IGF-I) and 
of active TGF-β. These changes appear to take place late in the sequence of events 
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resulting in PDR and are not restricted to diabetes; they were also detected in other retinal 
hypoxic diseases 50. TGF-β1 has been shown to participate in the pathogenesis of DR 51,52. 
A role for TGF- β1 has been shown in the microvascular complications of type 1 diabetes 
53,54.  In addition, hyperglycemia induces protein kinase C (PKC) activation, which results 
in increased microvascular protein buildup by up-regulating TGF-β1, fibronectin and type 
IV collagen 55,56. Serum protein influx due to hypoxia is likely the reason for vitreous 
alterations of active TGF-β 50.  
It has been indicated that TGF-β appears to decrease the tightness of the inner blood retinal 
barrier (iBRB) 57. Intravitreal levels of Angiopoietin-2 have been shown to be significantly 
associated with VEGF and TGF-β1 concentration in DR patients undergoing vitrectomy. 
This suggests that these factors could be involved in promoting retinal angiogenesis 
synergistically 51.  
Numerous studies have demonstrated that markers of angiogenesis and inflammation 
associate with the incidence of diabetes. In this study, VEGF, Leptin, Ang 2, HGF/SF, 
EGF, IL-8, ICAM-1, HB-EGF and TGF-β have been investigated. One of the initial events 
in diabetic retinal inflammation is the adhesion of leukocytes to the microvascular 
endothelium. Increased leukocyte adhesion leads to loss of endothelial cells and breakdown 
of the blood-retinal barrier 37,58. The leukocyte adhesion in the diabetic retina is assisted by 
the increased upregulation of adhesion molecules such as ICAM-1 36. VEGF has been the 
most extensively investigated biomarker in relation to the alteration of the blood retinal 
barrier. VEGF also triggers elevated leukostasis in the retinal microvessels 5. A cellular 
experiment study showed that Ang 2 stimulates monocytes adhesion by sensitizing 
endothelial cells for TNF-α and modulates the TNF-α-induced up-regulation of ICAM-1 59.
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HGF is an endothelium specific growth factor with more potent mitogenic activity than that 
of basic fibroblast growth factor (b-FGF), VEGF, interleukin 6 (IL-6), and interleukin 1 
(IL-1) 32,33. 
The aim of this study was to determine disturbance of inflammatory and angiogenic 
vascular biomarkers in the aqueous humor in patients with relatively early DR and in 
healthy age-matched controls. This will help to better understand the pathophysiology of 
DR.   
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6.2 Methods 
6.2.1 Sample 
This study received approval by the University of Waterloo Office of Research Ethics and 
the Research Ethics Board of the University Health Network, University of Toronto, 
Canada. Informed consent was obtained from each subject after explanation of the nature 
and possible consequences of the study according to the tenets of the Declaration of 
Helsinki. The sample consisted of 33 volunteers in two groups of subjects with mild-to-
moderate NPDR (n=15; mean age 69.11; SD 6.58 years) and aged matched healthy controls 
(n=18; mean age 67.86; SD 6.17 years) who were listed for routine cataract extraction with 
pseudo-intraocular lens implantation. The eye of each subject that underwent cataract 
surgery was selected for the study. All subjects had a corrected visual acuity of 20/40, or 
better, post-surgery. Subjects were excluded for a family history of any other ocular 
disease, apart from diabetic retinopathy. None of the patients with NPDR had received 
treatment of any kind for their retinopathic changes or had any evidence of diabetic 
macular edema or any other sight-threatening DR characteristic.  
6.2.2 Assessment of Cytokines in Aqueous Humor (AH) 
Aqueous humor is essential for the metabolic homeostasis, physiologic and nutritional 
maintenance in the anterior chamber. Components of the aqueous humor can likely reflect 
the state of intraocular tissues and represent any biochemical alteration due to ocular 
diseases. Aqueous humor samples can provide information with minimal risk as an 
outpatient process for the evaluation of abnormal cytokines or inflammatory biomarkers in 
various ocular diseases with or without a systemic association 36. 
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Undiluted samples of AH were obtained (by Drs. Singer and Brent) from patients 
proceeding to cataract surgery.  Briefly, a paracentesis was made in the peripheral cornea 
next to the limbus at the onset of surgery. A Sautter hydrodissection cannula (27G, 
0.4x22mm; Geuder, Heidelberg, Germany) was introduced into paracentesis tract to deliver 
suction by pulling up the plunger. The tip of the cannula was placed in the mid anterior 
chamber and 20-150µl of AH was slowly aspirated. The AH was collected into the attached 
syringe and transferred consequently into an eppendorf tube of 1.5ml where it was 
assessed.  
6.2.3 Measurement of Cytokines Using Multiplex Analysis 
Multiplexed bead-based immunoassay was utilized for the simultaneous measurement of 
10 cytokines (VEGF-A, VEGF-C, VEGF-D, Leptin, Ang 2, HGF/SF, IL-8, EGF, TGF-β1 
and TGF-β1) within each AH sample (Bio-Rad Laboratories, Inc., Hercules, CA). The 
multiplex technology is based on internally color-coded microspheres coupled to analyte-
specific antibodies, permitting the simultaneous measurement of multiple analytes for each 
sample. Wherever the measured values dropped below the threshold of detection, we set 
the recorded concentration at the limit of detection. Cytokines for which the majority of 
concentrations were at or below the limit of detection were considered non-measurable. 
6.2.4 Statistical Analysis 
AH cytokine levels are reported as mean (pg/mL) ± standard deviation. Statistical 
significance was considered when p  ≤  0.05. Differences in the distribution of cytokines 
between groups were analyzed by the Student’s t-test. 
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6.3 Results 
Using a multiplexed magnetic bead immunoassay (Luminex), the levels of 15 cytokines 
within AH samples of NPDR patients and their aged-matched controls were measured. The 
complete dataset of cytokine expression is summarized in Table 6.1.  
Of the 12 cytokines and chemokines analyzed in the vitreous of controls and NPDR 
patients, the levels of 2 cytokine (VEGF-D and ICAM-1) were considered unmeasurable, 
as the majority of AH sample concentrations were at or below the limit of detection. Of the 
12 cytokines with measurable levels, there were 6 cytokines with a mean AH concentration 
significantly higher in NPDR patients when compared to controls (Table 6.1). Ang 2, IL-8, 
HGF and HGF were significantly higher in NPDR patients than in control patients 
(p=0.005, p=0.034, p=0.017, p=0.018, respectively) but EGF was significantly lower 
(p=0.025) in NPDR patients than in control patients. No significant difference was found in 
VEGF-A, VEGF-C, Leptin, and HB-EGF levels between the two groups (p=0.342, 
p=0.757, p=0.151, p=0.957, respectively). The magnitudes of the difference in range 
between the two groups for each cytokine are reported in Table 6.1. 
The aqueous humor concentrations of ICAM-1 were reported to be either out of range or 
below the range for most of the subjects in both groups suggesting that AH was much 
diluted to pick up the values.  
The aqueous humor concentration of ICAM-1 for the subjects that were not out of range 
was: mean NPDR group 474.92±470.02 ranged from 4.90 to 944.94 with only two NPDR 
patients showing ICAM-1 concentrations. However, the result indicated a significant 
increase in the aqueous humor levels of both TGF-β1 and TGF-β2.  
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Cytokine Control NPDR p-value 
Angiopoietins-2 12.46±5.37 21.84±11.58 0.005 
VEGF-A 82.02±47.38 127.33±192.98 0.342 
VEGF-C 4.87±2.31 5.14±2.57 0.757 
VEGF-D OOR OOR − 
HGF/SF 121.68±53.37 250±201.57 0.018 
IL-8 1.14±0.51 2.46±2.40 0.034 
EGF 0.24±0.096* 0.17±0.074* 0.025 
Leptin 34.82±27.33 73.00±96.00 0.150 
TGF-β1 5.94±2.43 18.46±13.74 0.004 
TGF-β2 2336.21±1201.99 4689.38±1426.36 <0.001 
ICAM-1 OOR 470.92±470.02 − 
Hb-EGF 0.80±0.24 0.81±0.49 0.956 
 
Table 6.1 AH levels of Cytokines in subjects. Cytokine levels in pg/mL ± SD (range in cytokine values). 
OOR represents Out of range (in this case was lower in the range). *The values reported were below the 
range but detectable.  
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6.4 Discussion 
VEGF is a well-known persuasive angiogenic factor that stimulates retinal 
neovascularization, leading to tractional retinal detachment and vitreous hemorrhage, 
which are important because they represent the most severe causes of visual loss in patients 
with PDR 4,5. Previous studies have indicated that VEGF concentrations are higher in the 
aqueous humor and the vitreous of diabetic patients and that the severity of DR is intensely 
associated to the VEGF concentrations. To add up, VEGF plays an important role in both 
NPDR and PDR 5,60-64. However, our study found no significant difference in VEGF 
concentrations between NPDR patients and age-matched controls. This finding is 
consistent with other studies. Selim and co-workers did not find any difference between 
controls and diabetic patients without DR; however, they found a difference between 
controls and diabetic patients with DR 65. Shinoda and co-workers also did not find a 
significant difference in the AH levels of VEGF 63. Basically, this might be explained by 
the wide variation in severity of mild-to-moderate NPDR in our study sample. It has been 
reported that TGF-β controls release of VEGF by glioma cells in an activin-receptor-like-5-
dependent (ALK-5-dependent) approach involving SMAD2, SMAD3, and SMAD1/5/8 
signaling 66. It has also been reported that VEGF gene expression at a transcriptional level 
can be synergized by both TGF-β and hypoxia signaling pathways 67. It has been shown 
that TGF-β1 down-regulated VEGF-D expression in human lung fibroblast 68. Although the 
reason for this discrepancy is uncertain, one possibility is that the methods for 
measurement and the tissues of interest are different. It has been shown that hyperglycemia 
does not have any impact on hypoxia-inducible factor (HIF-1α) 69. It is thought that HIF-1α 
activation plays a role in the up-regulation of angiogenic factors causing neovascularization 
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70.  
Hypoxia, VEGF 71 and retinal ischaemia 17 induce Ang 2. VEGF has been shown to initiate 
neovascularization and to increase the effect of the angiopoietins 72. The present study is 
the first report of the concentration of angiopoietins in the AH samples of mild-to-moderate 
NPDR. However, there are studies in vitreous20 and serum samples73 that have shown 
significant increase in the level of Ang 2 of NPDR patients. Ang 2 promotes pericyte loss 
under high glucose conditions in DR 19. It is hypothesized that Ang 2 stimulates 
neovascularisation and induces vascular permeability 20. Hypoxia-inducuction Ang 2 might 
explain the higher concentration of Ang 2 within the NPDR group.  
Leptin is a circulating hormone, which is secreted mostly from adipose tissues. It has been 
reported that leptin is an angiogenic factor and its level in vitreous have been shown to be 
higher in patients with proliferative diabetic retinopathy 3. Another study implied the 
possibility of a role for leptin in angiogenesis through VEGF induction as well as PEDF 
suppression in pericytes. Therefore, leptin could be a factor in the development and 
progression of DR, especially in obese insulin-resistant patients 74. Nonetheless, this study 
did not find a significant difference in leptin levels between mild-to-moderate NPDR and 
controls. This might be explained by the VEGF levels, which were not significantly higher 
in NPDR patients either.  
In the present study, aqueous HGF levels have been shown to increase in NPDR group 
when compared to controls. HGF has been crucially indicated in the development of 
proliferative retinal diseases 75,76. Katsura and co-workers found increased HGF levels in 
the vitreous fluid of patients with proliferative diabetic retinopathy 34. HGF levels were 
significantly increased in the NPDR group when compared to control group 77. HGF as well 
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as VEGF have been introduced as the key factors playing a role in retinal vascular 
permeability 78,79. It has been reported that HGF can prevent hypoxia-induced apoptosis by 
inhibiting caspase-8 through: 1) p38 mitogen-activated protein kinase (MAPK) 
phosphorylation and 2) blocking Bax translocation 80. HGF is a multi-potential cytokine 
that can promote bioactivities, including junctional breakdown, cell survival, migration, 
cell scattering, and invasive behavior. It has been involved in various events in tissue 
development/maintenance, homeostasis, and wound healing 81,82. Increased HGF might be 
explained as either body’s feedback to fight the insult produced by hyperglycemia 83.  
It has been reported that IL-1β might up-regulate IL-8 in Müller cells through the p38 
mitogen-activated protein kinases (p38 MAPK) and ERK1/2 pathways 84 (ERK1/2 is a 
significant member of mitogen-activated protein kinases that control a broad range of 
cellular activities and physiological processes). Aqueous concentrations of IL-8 have been 
shown to be higher in the NPDR patients 85, which is consistent with our result. 
EGF levels were significantly lower in NPDR patients. The lower EGF concentrations were 
lower than the range which might be explained by diluted environment of the AH samples. 
Any change in the signalling pathway of EGF might cause apoptosis and hence cell death. 
It has been also shown that EGF signaling inhibition protects the retina against insulin-
induced vascular leakage in diabetes 86. The EGF decrease might also be explained as 
body’s immune system protective response in diabetes.  
A possible explanation for HB-EGF not being upregulated might be that HB-EGF might be 
translocated to nuclear envelope 87.   
TGF-β can induce angiogenesis when bind to ALK1, whereas ALK5 develops reverse 
outcomes on endothelial cell behavior. However, it has been reported that endoglin 
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(transmembrane accessory receptor for TGF-β) promotes ALK1 signaling 88. Endoglin was 
not upregulated in this study (p=0.261), which might suggest an anti-angiogenic role of 
TGF-β during mild-to-moderate NPDR. TGF-β can also bind to EGFR. An 
immunohistochemical study on human colon adenocarcinoma showed an inverse 
correlation between TGF-β-EGFR/ErbB signaling 89, which might indicate anti-angiogenic 
behaviour from TGF-β when adhered to EGFR. 
Altogether, our findings of increased concentrations of Ang 2, HGF, TGF-β and IL-8 or 
decreased levels of EGF in NPDR patients suggest an important role of these molecules in 
the pathophysiology of DR before the clinical advent of neovascularization and DME. 
 
Biomarker of Interest Reason for Biomarker Evidence / Motivation Reference 
VEGF 
Permeability / Neovascularization/ 
Hypoxia/ Leukostasis/ 
HIF-1 has crucial role in VEGF production / 
basement membrane thickening 
Human / 
Animal 
4-13 
49,90 
ICAM-1 Leukostasis / Increased during hypoxia Human / Animal 
36 
Leptin Angiogenesis stimulator Human / Animal 
74 
Ang 2 Neovascularization / Pericyte loss / Vascular permeability / monocytes adhesion 
Human / 
Animal 
19,20,59,71-73 
HGF DR progression / vascular permeability / anti- and pro-apoptosis 
Human / 
Animal 
75,78-82 
HB-EGF Possible transactivation of HGF/c-met /  Microcirculatory blood flow regulator 
Human / 
Animal 
91,100 
EGF Insulin-induced vascular leakage in DR /  Potent mitogen role 
Human / 
Animal 
92,99 
IL-8 
Neutrophil transmigration / neovascular 
growth / retinal glial cells reactively secrete 
IL-8 in response to hypoxia / mediate 
angiogenesis via both VEGF dependent and 
independent mechanisms 
Human / 
Animal 
93-97 
TGF-β 
Inhibition of proliferation of müller glial 
cells / basement membrane thickening / 
decrease the tightness of iBRB 
Human / 
Animal 
49,57,98 
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7  Retinal Blood Oxygen Saturation and Aqueous Humor Biomarkers in 
Early Diabetic Retinopathy 
 
Faryan Tayyari, Lee-Anne Khuu, Jeremy Sivak, Shaun Singer, Michael Brent, John 
Flanagan, Christopher Hudson 
 
 Design Recruitment 
Acquisition 
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Publication 
F. Tayyari x x x x x 
L. Khuu x x x x  
J. Sivak x   x  
S. Singer  x x   
M. Brent  x x   
J. Flanagan x     
C. Hudson x   x x 
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7.1 Introduction 
Diabetic retinopathy (DR) remains the most common microvascular complication of 
diabetes and despite significant and advancing research efforts the precise pathology of DR 
is still not fully understood. One of the suggested pathologies of DR is a direct 
consequence of hypoxia initiated by hyperglycemia 1-3. 
The retinal high oxygen demand is thought to contribute to the particular vulnerability of 
the retina to vascular disease. DR appears to be allied closely to disturbances in the 
vasculature. Hence, a variety of studies have considered the inner retinal blood flow as a 
potential biomarker of DR. However, the results of inner retinal blood flow disturbance in 
DR have been contradictory 4-13, although virtually all indicate some aspect of disturbance. 
The study of metabolic disturbance as a functional diagnosis is an encouraging conduit for 
improved understanding the pathophysiology behind the disease. One of the practical 
factors of the microcirculation that reflects metabolic activity is the blood oxygen 
saturation. There is a need to study the oxygen supply to the retinal vasculature in diabetes 
as an improved way to understand the metabolic disturbances associated with this disease.   
The early phase of the disease, clinically labeled non-proliferative diabetic retinopathy 
(NPDR), is characterized in part by retinal swelling consequent to the leakage and increase 
of extracellular fluid and proteins in the macula. Exudation develops from structural 
transformations in the retinal vascular endothelium that causes the breakdown of the blood-
retina barrier (BRB) and an escalation in vascular permeability 14-16. 
It is thought that change in blood circulation may lead to functional damage and broad 
retinal tissue impairment and disturbance during diseases such as DR 17.  
Aqueous humor (AH) is essential for the metabolic homeostasis, physiologic and 
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nutritional maintenance in the anterior chamber. Components of the AH can likely reflect 
the state of intraocular tissues and can represent any biochemical alteration due to ocular 
disease. AH samples can provide information with minimal risk as an outpatient process 
for the evaluation of abnormal cytokines or inflammatory biomarkers in various ocular 
diseases with or without a systemic association. 18 
Vascular endothelial growth factor (VEGF) is a key regulator of vascular growth in 
angiogenesis and vasculogenesis 19 and hypoxia is the crucial regulator of VEGF-
stimulated neovascularization 20. This established persuasive angiogenic factor also plays a 
role in blood-retina-barrier (BRB) permeability in DR. Vascular hyper-permeability 
secondary to tight junction impairment between vascular endothelial cells and also 
neovascularization are bold symbols of vascular endothelial cell dysfunction induced by 
diabetes. VEGF plays an important role to mediate these early and later vascular alterations 
21-23.  Previously, VEGF has been reported to be significantly increased in diabetes and a 
correlation between the levels of VEGF and DR severity has been shown 24. Angiogenesis 
is caused by disruption between the production of angiogenic activator such as VEGF and 
angiogenic inhibitors such as angiostatin and pigment epithelium-derived factor (PEDF) 
25,26. The amplified production of angiogenic activators and reduced production of 
angiogenic inhibitors caused by local hypoxia, disturbs the balance between the desirable 
and undesirable regulators of angiogenesis. Subsequently, over proliferation of capillary 
endothelial cells occurs which leads to neovascularisation 26. 
Transforming growth factor-beta (TGF-β) is another angiogenic factor that participates in 
the pathogenesis DR 27-28. The role of TGF-β1 has been shown in microvascular 
complications with type 1 diabetes 29,30. In addition, hyperglycemia induces PKC activation, 
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which results in increased microvascular protein by up-regulating TGF-β1, fibronectin and 
type IV collagen 31,32. Serum proteins influx due to hypoxia and this probably explains the 
vitreous alterations of active TGF-β32. Pfeiffer and co-workers reported that TGF-β2 was 
reduced 30% and 70% in PDR and non-diabetic retinal ischemia patients, respectively 33. 
TGF-β, especially TGF-β2, is anti-angiogenic and is an anti-inflammatory cytokine in the 
eye 34.  
The angiopoietins are growth factors that regulate the development of physiological 
angiogenesis and pathological neovascularization 35,36. Another study suggested a 
relationship between Ang 2 and VEGF with angiogenic activity in PDR 37. Others implied 
that Ang 2 is expressed by hypoxia and VEGF in bovine aortic endothelial cells 38. 
Leptin, an adipocyte-derived hormone, is an energy metabolism regulator and is associated 
to diabetes mellitus through its metabolic actions. Leptin stimulates endothelial 
proliferation and angiogenesis 39. Results describing the association between serum leptin 
and diabetic micro-angiopathies are variable. Sari and co-workers 40 did not find any 
difference in the leptin levels in serum between patients with and without diabetic 
nephropathy, retinopathy and neuropathy. Furthermore, Asakawa and co-workers 41 
reported no relationship in leptin levels and micro-angiopathies in patients with type 2 
diabetes of Japanese descent. However, Freuhwald-Schultes and co-workers 42 reported 
high serum leptin amounts in type 2 diabetic patients and early stages of renal disease, (i.e., 
micro-albuminuric and macro-albuminuric nephropathy), while serum leptin levels did not 
significantly show any association with diabetic neuropathy. Jung and co-workers 43 did not 
find any relationship between leptin concentrations and diabetic retinopathy.  
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A complicated series of interactions between retinal cells with growth factors and 
cytokines, extracellular matrix proteins and metallo-proteinases trigger the development of 
proliferative retinal diseases 44-46. HGF is one of these growth factors that has been studied. 
Its receptor is the c-met, a transmembrane tyrosine kinase 47.  An elevated HGF level in 
patients with type 1 diabetes mellitus with PDR and the relationship between progression 
of DR and the concentration of HGF was suggested as a role of HGF in the pathogenesis of 
PDR 48. 
It has been reported that HGF is an endothelium specific growth factor with more potent 
mitogenic activity than that of basic fibroblast growth factor (b-FGF), VEGF, interleukin 6 
(IL-6), and interleukin 1 (IL-1) 49,50. Furthermore, the HGF concentration in the vitreous of 
patients with PDR has been shown to be higher when compared to non-diabetic subjects51. 
In addition, it has been suggested that HGF might affect the progression of DR 52. 
It has been stated that the insulin-induced vascular leakage can be prevented by EGF 
inhibition 53. It has been reported that AGE could trigger EGF receptor (EGFR) 54,55. The 
EGRF can bind to multiple growth factors such as EGF, HB-EGF 56. ROS might block 
EGFR dephosphorylation 57.  
The aim of this study was to evaluate retinal blood oxygen saturation levels and aqueous 
humor concentrations of inflammatory cytokines in diabetic patients with non-proliferative 
diabetic retinopathy (NPDR) and to compare them with those of control subjects. The non-
invasive quantification of retinal oxygenation is feasible using spectral imaging techniques 
and will be compared to ocular angiogenesis biomarkers, which in turn may offer an 
alternative sensitive and predictive biomarker of DR severity.  
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Numerous studies have demonstrated that markers of angiogenesis and inflammation 
associate with the incidence of diabetes. It is critical to note that inflammation occurs 
before ophthalmoscopic signs of DR but assessment of inflammatory markers is invasive 
and not a routine procedure, therefore, it is important to find a technique, which is non-
invasive to be able to detect DR before its morphological signs.  
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7.2 Methods 
7.2.1 Sample 
This study received approval by the University of Waterloo Office of Research Ethics and 
the Research Ethics Board of the University Health Network, University of Toronto, 
Canada. Informed consent was obtained from each subject after explanation of the nature 
and possible consequences of the study according to the tenets of the Declaration of 
Helsinki. The sample consisted of 32 volunteers in two groups of subjects with mild-
moderate NPDR (n=14; mean age 69.11; SD 6.58 years) and aged matched healthy controls 
(n=17; mean age 69.70; SD 6.26 years). The eye of each subject that underwent cataract 
surgery was selected for the study. All subjects had a corrected visual acuity of 20/40 or 
better. Subjects were excluded for family history of any other ocular disease, apart from 
diabetic retinopathy. None of the patients with NPDR had received treatment of any kind 
for their retinopathic changes or had any evidence of diabetic macular edema or any other 
sight-threatening characteristic.  
Group Group Mean Age (SD) 
Male to Female 
Ratio 
Group Mean A1c 
(SD) 
Duration of DR 
(SD) 
Control 69.70 (6.26) 8 M : 9 F 5.5 (0.4) - 
NPDR 69.11 (6.58) 6 M : 8 F 7.5 (1.5)* 13.2 (8.3)* 
Table 7.1 Group mean age, male to female ratio and A1c (A1c: glycosylated hemoglobin. M; male, F; 
Female. NPDR; Non-proliferative diabetic retinopathy) *(difference between control and NPDR group 
p<0.001) 
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7.2.2 Assessment of Retinal Blood Oxygen Saturation  
Details of the SO2 measurement and cube registration have been described elsewhere 
(Chapter 4). A prototype custom-built fundus camera (H-8.5 HR Camera, Optina, QC, 
Canada) is the foundation of the hyperspectral imaging system that incorporates a tunable 
laser source (TLS) as the light source. The TLS makes it possible to transfer wavelengths 
within a spectral range of 400-1000nm (visible to IR) and with a half peak bandwidth of 
2nm. The TLS is built on Photon etc’s Bragg grating filtering technology which permits 
rapid wavelength presentation from the steady and powerful super-continuum light source 
(Leukos-SM-30-OEM, Leukos Innovative Optical Systems, Limoges, France). The TLS 
can be electronically tuned with an operating ambient temperature of 10-30°C. An 
automatic spectral system is incorporated into the system to achieve exact and accurate 
(<1nm) wavelength choice. The sensitive 1.3MPixel (1392 x 1040 pixel) 14-bit CCD 
camera (Pixelfly USB, PCO AG, Kelheim, Germany) used in this system is for high 
definition imaging.  The imaging system is operated by using PhySpec (Photon Etc, 
Montreal, QC, Canada), a software programme that manipulates the Bragg tunable filter 
(BTF) and CCD camera to allow aspects such as operator defined wavelength range and 
wavelength interval. A low power white light source (delivering about 100mW over 420nm 
to 2400nm) and the Bragg Tuneable Filter are used to exclude the use of conventional flash 
lamp, and therefore all images are acquired at low light levels, thereby minimizing any 
potential change of the metabolites and photopigment status in the eye. A diagonal field of 
view of approximately 37.4° is sustained by the opto-mechanics of the system 58. 
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7.2.3 Procedures 
This was a cross-sectional study and all participants attended for two visits. The eye 
selected to undergo surgery was assigned to be the study eye. The first visit was at the time 
of cataract surgery to collect the aqueous humor. The second visit was to assess the 
magnitude of retinal oxygen saturation and retinal blood flow. The follow-up imaging visit 
was 4-6 weeks after the surgery to ensure that participants are not using NSAIDs and / or 
topical steroids.  
Visit 1: Undiluted samples of AH were obtained from patients proceeding to cataract 
surgery.  Concisely, a paracentesis was made in the peripheral cornea next to the limbus at 
the onset of surgery. A Sautter hydrodissection cannula (27G, 0.4x22mm; Geuder, 
Heidelberg, Germany) was introduced into the paracentesis tract to deliver suction by 
pulling up the plunger. The tip of the cannula was placed in the mid anterior chamber and 
50-150 µl of AH was slowly aspirated. The AH was collected into the attached syringe and 
transferred consequently into an eppendorf tube of 1.5ml.  
Visit 2: refraction, logMAR visual acuity, Goldmann applanation tonometry and resting 
blood pressure were assessed prior to dilation of the study eye. The pupil of the study eye 
was dilated using Tropicamide 1% (Alcon, Mississauga, Canada) at the beginning of 
second visit to achieve an adequate view of the fundus for the image acquisition. A 
minimum of six oximetry measurements was acquired. 
7.2.4 Measurement of Cytokines Using Multiplex Analysis 
Multiplexed bead-based immunoassay was utilized for the simultaneous measurement of 5 
cytokines (Angiopoietin 2, HGF/SF, IL-8, TGF-β1 and TGF-β2) within each AH sample 
(Bio-Rad Laboratories, Inc., Hercules, CA). The multiplex technology is based on 
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internally color-coded microspheres coupled to analyte-specific antibodies, permitting for 
the simultaneous measurement multiple analytes for each sample. Wherever the measured 
values dropped below the threshold of detection, we set the recorded concentration at the 
limit of detection. Cytokines for which the majority of concentrations were at or below the 
limit of detection were considered non-measurable. 
7.2.5 Statistical Analysis 
AH cytokine levels are reported as mean (pg/mL) ± standard deviation. Statistical 
significance was considered when p  ≤  0.05. Significant correlations between biomarkers 
and retinal oxygen saturation were analyzed using bivariate Pearson correlation and linear 
regression. All significant associations are inserted into a multiple regression model to 
assess whether the dependent variable (SO2) could be predicted from biomarkers 
(independent variables). A Pearson correlation coefficient value of r>0.3 and p≤0.05 was 
considered statistically significant. 
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7.3 Results 
Group mean values for the SO2 and biomarkers are found in Table 7.2. 
 
Oxygen Saturation Control NPDR T-test (p-value) 
SO2 (Arteriole) 92.97±1.6 94.65±2.2 0.015 
SO2 (Venule) 55.90±4.8 63.30±5.6 <0.001 
AV Difference 37.05±4.95 30.57±4.76 0.001 
Biomarkers Control NPDR T-test (p-value) 
VEGF-A 82.02±47.38 127.33±192.98 0.342 
HGF 121.68±53.37 250±210.57 0.018 
IL-8 1.14±0.51 2.46±2.40 0.034 
Ang 2 12.46±5.37 21.85±11.16 0.005 
Leptin 34.82±27.34 73.00±96.00 0.151 
Hb-EGF 0.80±0.24 0.81±0.49 0.956 
EGF 0.24±0.09 0.17±0.07 0.025 
ICAM-1 OOR 470.92±470.02 − 
TGF-β1 5.94±2.43 18.46±13.74 0.004 
TGF-β2 2336.21±1201.99 4689.38±1426.36 <0.001 
Table 7.2 Group mean values for blood oxygen saturation and aqueous humor biomarkers. OOR represents 
out of range. Bold values are significant.  
Retinal blood oxygen saturations as a function of biomarkers are illustrated in Figure 7.1. 
Please note that due to a limitation of AH amount some of the biomarkers are are of limited 
predictive value (for example TGF- β1, TGF- β2 are only performed on 8 NPDR subjects). 
A significant correlation was taken at r>± 0.30 and p<0.05. The correlation was 
investigated for biomarkers that are significantly different between the groups of controls 
and NPDR. The r scores are summarized in Table 2.  
Controls HGF IL-8 Angiopoietin 2 EGF TGF-β1 TGF-β2 
SO2 
(Venule) 
0.1774 
(0.496) 
0.4337 
(0.082) 
0.1507 
(0.564) 
-0.1665 
(0.523) 
-0.1952 
(0.643) 
0.0723 
(0.806) 
SO2 
(Arteriole) 
-0.0654 
(0.804) 
0.0284 
(0.914) 
-0.2166 
(0.404) 
0.1526 
(0.559) 
0.01150 
(0.768) 
0.1116 
(0.704) 
NPDR HGF IL-8 Angiopoietin 2 EGF TGF-β1 TGF-β2 
SO2 
(Venule) 
0.5196 
(0.050) 
0.2337 
(0.4213) 
0.5477 
(0.042) 
-0.5520 
(0.040) 
0.5512 
(0.156) 
0.2029 
(0.692) 
SO2 
(Arteriole) 
0.2897 
(0.315) 
0.2589 
(0.371) 
0.4803 
(0.082) 
0.102 
(0.717) 
0.348 
(0.398) 
0.3419 
(0.231) 
Table 7.3 Pearson correlation values r and statistical significance (p) between baseline levels of biomarkers. 
The p-values are reported in (). 
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Figure 7.1 Retinal blood oxygen saturations as a function of biomarkers (NPDR; Non-proliferative diabetic 
retinopathy). Please note the difference in horizontal axis scaling for HGF. The number of subjects varies 
across assays.  
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Repeat measurement range 
values Control NPDR 
Ang 2 5.58 to 7.72 22.00 to 24.18 
EGF 0.13 to 0.24 0.08 to 0.15 
Hb-EGF 0.13 to 0.76 0.29 to 0.49 
IL-8 0.48 to 1.02 0.69 to 0.81 
HGF 58.05 to 104.51 181.17 to 186.70 
Leptin *OOR to 67.57 67.57 to 110.79 
TGF-β 1 NA 16.25 to 16.76  
TGF-β 2 NA 5415.97 to 5559.45 
Table 7.4 This table represents the repeat meaurement values reported for one control and one NPDR 
(NPDR; Non-proliferative diabetic retinopathy). The sample volumes were low and this made it impossible to 
run subjects other than the two in the Table more than once. * One of the values was out of range (OOR) and 
the other one was reported in the standard range. NA; not applicable.  
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7.4 Discussion 
Simultaneous retinal blood flow measurement and retinal hemoglobin oxygenation are 
required to assess absolute values (i.e. net oxygen delivery) of oxygen delivered to the 
retina 59,60. 
The increasing number of people with diabetes in the world indicates that DR remains an 
on-going major sight-threatening consideration. The pathogenesis of DR is a common 
cause of visual loss worldwide and a number of hyperglycemia-related pathways have been 
associated with the onset and progressions of DR. Disturbances in the vasculature appear to 
play a vital role in DR. Therefore, many studies have investigated the inner blood flow. 
Due to the contradictory nature of previous work on retinal blood flow 4-13; this study 
investigated retinal blood oxygen saturation as a function of biomarkers in AH in DR. This 
might aid a better understanding of the pathophysiology of DR.  
To our knowledge, this is the first study that investigates the association between retinal 
blood oxygen saturation and aqueous humor angiogenic / inflammatory biomarkers in 
human NPDR. The result of the present study showed a correlation between SO2 and HGF, 
Ang 2 and EGF in NPDR (Table 7.2).  
Even though the Pearson r for TGF-β2 as a function of SO2 was 0.5512, the associated p-
value (0.156) did not reach significance. This might be explained with the low number of 
subjects in that group; the AH amount was not sufficient for some subjects to allow valid 
assay.  
This study showed a relationship between SO2 and HGF. It has been found that local 
release of HGF has a regulatory effect on the glucose metabolism via Met activation 61. Met 
is the surface receptor for HGF and is associated to the insulin receptor (INSR) tyrosine 
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kinase 61. It has been indicated that HGF can prevent hypoxia-induced apoptosis by 
inhibiting caspase-8 by: 1) p38 mitogen-activated protein kinase (MAPK) phosphorylation 
and 2) blocking Bax translocation 62. HGF is expressed following hypoxic conditions and 
the hypoxic tissues consume less oxygen and hence more oxygen remains in the blood. In 
other words, HGF might be expressed to reduce the apoptosis as an immune response (high 
volumes of HGF). This is thought to occur under hypoxic conditions. Cells are insulted by 
hypoxia and are then thought not to function fully and therefore do not use oxygen to its’ 
usual capacity.  This also could mean that since apoptosis is reduced, there is a chance that 
some of these cells that are malfunctioning, consume / “steal” oxygen at an exaggerated 
rate and this could result in the death of normal / less affected cells. The proapoptotic 
aspect of HGF appears to be associated to HIF-1 deficiency with loss of signaling functions 
63. These factors might play a role in the relationship between SO2 and HGF concentrations 
in AH.  
The other biomarker that has a relationship with the amount of retinal blood oxygen is 
Angiopoietin 2. Ang 2 promotes pericyte loss under high glucose conditions in DR 64. The 
pericyte loss will result in less oxygen demand and hence increased oxygen in the vessels. 
There is also evidence that up-regulation of Ang 2 in the absence of VEGF results in 
endothelial cell death and vascular regression. This leads to hypoxic retinal conditions and 
in turn less oxygen demand by the tissue, which will result in higher SO2 in the vessels.  
Another biomarker of interest that showed an association with SO2 levels was EGF. It has 
been reported that AGE could trigger EGF receptor (EGFR) 54,55. The EGRF can bind to 
multiple growth factors such as EGF, HB-EGF 56. ROS might block EGFR 
dephosphorylation 57. This might lead to elevated EGF release by the body as a feedback to 
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blockade EGFR. It has also been reported that EGF exerts anti-apoptosis benefits to 
podocytic injury affected by high glucose 65. This study revealed that EGF levels in NPDR 
are lower when compared to controls that result in apoptosis. This might explain the 
inverse relationship between EGF and SO2 and more retinal blood oxygen saturation. 
Limitations: One of main challenges of the AH results is that only a small amount of AH 
can be attained from human eyes. Normally 50-150 µl of AH can be acquired from one 
eye, which is hardly adequate to assess a limited number of cytokines using traditional 
ELISA. However, with the flow cytometric bead-based technology, several cytokine 
analytes can now be measured simultaneously in a single sample. Even so, more sample 
volume was required for performing all the different assays described in this study.  
Another limitation of this study was the delay between the acquiring AH and imaging visit. 
However, this is unlikely because the patient sample has slowly progressing, early DR.  
There might be other factors affecting the results, such as diet, when compared to the first 
visit (surgery day), despite advice from the student investigator to minimize such sffects. 
In summary, HGF, EGF and Ang 2 showed a correlation with retinal blood oxygen 
saturation. Hypoxic conditions lead to HGF expression and less oxygen is consumed due to 
cell death in hypoxic tissues. The proapoptotic characteristic of HGF might be associated to 
HIF-1 deficiency 63. EGF reduction might cause apoptosis or distressed cell growth 
resulting in cell death and hence less oxygen consumption. Ang 2 stimulates pericyte loss 
under high glucose conditions in DR 64. There is also evidence that up-regulation of Ang 2 
in the absence of VEGF results in endothelial cell death and vascular regression. The 
pericyte loss and endothelial cell death might result in less oxygen demand and hence 
increased oxygen in the vessels. Pericytes are known as blood flow regulators, and their 
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loss will result in vasodilation and increased blood flow which might be involved in 
increased SO2 due to less time to release O2 to the tissues. The repeat measurement values 
for some samples were very poor based upon results from only two subjects (one control 
and one NPDR); however, most repeat values were acceptable to excellent (Table 7.3). 
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8   General Discussion 
Several non-invasive techniques have been developed to quantify ocular blood flow in 
humans. Previous techniques for measuring retinal blood flow have numerous limitations, 
such as being invasive (e.g. Fluorescein angiography), or are subjective (e.g. blue field 
entoptic phenomenon), or are incapable of calculating blood flow (e.g. Retinal Vessel 
Analyser) since a surrogate parameter of flow is measured.  In addition, the only technique 
that truly measures volumetric retinal blood flow is limited to relatively large vessels and a 
single measurement site.  To overcome these limitations, a new technique has been 
developed, generally known as Optical Coherence Tomography (OCT) blood flow 
technology. At this moment in time, however, no agreement has been reached regarding the 
exact clinical significance of change in retinal capillary blood flow. Indeed, the variability 
and repeatability of retinal capillary blood flow measurement needs to be established in 
order to define significant change and to use this technique in a clinical setting. OCT is a 
noncontact, non-invasive diagnostic technique that can be used to allow measurement of 
retinal blood flow. The development of Fourier-domain OCT (FD-OCT) considerably 
improved retinal imaging. Overall, we conclude that the FD-OCT gave repeatable 
measurements of retinal blood flow in normal subjects. The data was more repeatable for 
the younger age group (Chapter 3). 
Chapter 4 details the magnitude of retinal blood oxygen saturation (SO2) in DR and aged-
matched control subjects. A non-invasive prototype hyperspectral retinal camera (HRC, 
Optina, QC, Canada) was employed to assess the retinal blood oxygen saturation in NPDR 
and aged matched controls. For each subject, six repeated retinal images were acquired at 
wavelengths of 586 and 605nm using the HRC. There was a pronounced increase in SO2 
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values in both arterioles and venules in NPDR group. The A-V difference was lower in 
NPDR group. The pronounced increase in retinal blood SO2 in NPDR group might be 
explained possibly secondary to neuronal cell atrophy, in the diabetic group with mild-to-
moderate NPDR. 
Chapter 5 investigated the relationship between total retinal blood flow and retinal blood 
oxygen saturation. This study did not find any relationship between retinal blood flow and 
retinal blood SO2. 
The study of the relationship between retinal blood flow and retinal oxygenation in 
individuals with type 2 diabetes represents fertile scientific ground to be investigated and 
would greatly expand our understanding of the development of DR by enabling to calculate 
oxygen metabolism. Quantifying retinal blood oxygen saturation could help us better 
understand the pathophysiology behind retinal diseases such as DR; however, either 
oxygen saturation or retinal blood flow cannot be used to predict one another. This study 
emphasizes the need for quantifing both retinal blood flow and retinal oxygen saturation in 
ordr to calculate oxygen metabolism. 
The combination of retinal oxygen saturation and retinal blood flow can be used to extract 
more information about retinal metabolism since:  
Retinal O2 Delivery = [1.39 x Hb x SaO2 + (0.003 x PaO2)] x blood flow) 
Chapter 6 looks into the multiplex analysis of angiogenic and inflammatory biomarkers in 
AH of NPDR. Our findings suggest that up-regulation of Ang 2, IL-8, TGFβ, EGF and 
HGF in NPDR may play important roles in the pathophysiology of DR. These molecules 
could be considered to be studied further as therapeutic targets for the treatment and 
prevention of microvascular complications of DR. These findings helps to better 
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understand pathophysiology behind DR and validate oxygen saturation measurements.   
Chapter 7 studied the relationship between SO2 and angiogenic/inflammatory biomarkers in 
NPDR and compared it to control subjects. The findings of this study expand the existing 
knowledge to another level by adding the biomarker association. This study found a likely 
association between the biomarkers and SO2. This might be helpful for better 
understanding the pathophysiology behind DR. This study aids better understanding the 
pathophysiology of DR and validation of oxygen saturation measurements. The study of 
the relationship between inflammatory biomarkers and retinal oxygenation in individuals 
with type 2 diabetes emphasizes the need to expand our understanding of the development 
of DR by defining the interaction of inflammatory mediators and retinal oxygen saturation.  
In summary, quantifying retinal blood oxygen saturation could help us better understand 
the pathophysiology behind retinal diseases such as DR and possibly better non-invasive 
techniques to earlier diagnose of such diseases. 
 Limitations: 
1. One of main challenges of the AH results is that only a small amount of AH can be 
attained from human eyes. Normally 50-150 µl of AH can be acquired from one eye, which 
is hardly adequate to assess a limited number of cytokines using traditional ELISA. 
However, with the flow cytometric bead-based technology, several cytokine analytes can 
now be measured simultaneously in a single sample. Even so, more sample volume was 
required for performing all the different assays described in this study.  
2. Another limitation of this study was the delay between the acquiring AH and imaging 
visit. However, this is unlikely because the disease is early DR.  There might be other 
factors affecting the results, such as diet, when compared to the first visit (surgery day), 
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despite advice from the student investigator to minimize such sffects. 
3. The recruitment was challenging. Participants were already nerveous due to syrgery and 
did not wanted to make it more complicated. 
4. Another restriction was our sample size. It was challenging to recruit more subjects. 
Participants with DR usually had more complications and were excluded from the study. 
5. Due to small volume of AH, the assays were limited as well. Each assay needed at least 
40μl of AH. 
6. Another limitation was to simultaneously measure retinal blood flow and retinal oxygen 
saturation as opposed to sequential methods.  
8.1 Future work 
Future work should examine the simultaneous disturbance in SO2 and vascular 
inflammatory activity over a comprehensive longitudinal study. It is important to 
understand whether extended exposure to hyperglycemia could have a different effect on 
retinal blood oxygen saturation.  
Longitudinal studies that track changes in retinal blood oxygen saturation are important to 
better understand its relationship with the progression of DR. It will be also of significance 
to investigate the retinal blood oxygen saturation in different stages of DR and look at its 
association with the angiogenic biomarkers.  
The future work can expand the investigation to find a better way to understand the 
mechanism behind the receptors and look for the possible explanation for the behavior of 
biomarkers such as explore receptor for EGF and see if HB-EGF is binding to the EGFR 
instead of EGF during NPDR. 
	   127	  
FD-OCT was found to be repeatable and reliable when compared with other blood flow 
measurement instruments in other studies. However there is still a great need for a better 
instrument. The COV in young healthy participants was 7.5%, which is not negligible 
when it is required in clinical follow-up of patients. The difference between sessions of BF 
measurement will only be noticed if it is large during diseases. 
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Appendix A  
Methodology 
Procedure for sample collection 
Undiluted samples of AH were obtained from patients proceeding to cataract surgery.  
Briefly, a paracentesis was made in the peripheral cornea next to the limbus at the onset of 
surgery. A Sautter hydrodissection cannula (27G, 0.4x22mm; Geuder G-34245) was 
introduced into paracentesis tract to deliver suction by pulling up the plunger. The tip of the 
cannula was placed in the mid anterior chamber and 20-150µl of AH was slowly aspirated. 
The AH was collected into the attached syringe and transferred consequently into an 
eppendorf tube of 1.5ml where it was assessed.  
 
Analysis of angiogenic and inflammatory biomarkers 
Multiplex Immunoassays (Luminex, Bio-Rad Laboratories, Inc., Hercules, CA, Eve 
Technologies) 
Multiplex analysis was accomplished by the Bio-Plex 200 suspension array system. This 
system is built on a flow-based dual laser detector with real time digital signal processing 
and is capable of distinctive up to 100 diverse internally colour coded beads in a single well 
of a 96-well plate. This method is similar to sandwich-ELISA. Each polystyrene bead is 
conjugated with a distinctive reagent, particular to a specific bioassay. Each reactant is 
explicit for a different target analyte and this can comprise; antigens, antibodies, 
oligonucleotides, enzyme substrates, or receptors. A particular antibody bound to a bead 
aims a specific biomarker, which was again bind to a detection antibody with a fluorescent 
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reporter dye label. The simultaneous detection of many other analytes in the same sample is 
possible by different colored beads.  
To accomplish a multiplex assay, sample and reporter molecules are permitted to react with 
the conjugated bead mixture in microplate wells. The flow-based Bio-Plex 200 system 
recognizes each definite reaction based on bead color, and measures it. The dual detection 
flow cytometer is operated to settle the different assays by bead colors in one channel, and 
define of the analyte concentration by assessing the reporter dye fluorescence in another 
channel. The degree of the reaction is assessed using fluorescently-labeled reporter 
molecules also specific for each target analyte. Bio-Plex Manager software programmes 
data analysis and producing of thorough summary information.  
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